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Zusammenfassung 
Das Hepatozelluläre Karzinom (HCC) ist eines der aggressivsten und am weitesten 
verbreitetste Malignom was beim Menschen vorkommt. Weltweit ist das HCC die 
dritthäufigste Todesursache bezogen auf durch Karzinome verursachte Todesfälle. 
Ursachen hierfür sind aufgrund fehlender Therapieoption. Die vorliegende 
Dissertationsarbeit beschäftigt sich mit dem steigenden Bedarf an neuen Strategien, 
die eine frühe Erkennung und eine effektivere Behandlung von an HCC erkrankten 
Patienten ermöglichen. 
Eine Hauptursache des HCC ist die (komplette) Aufhebung der Methylierung, welche 
die Expression essentieller Gene auf der Transkriptionsebene beeinflusst. Studien 
haben gezeigt, dass das Chemotherapheutikum 5-Azacytidin (5-AZA), ein DNA 
Methyl Transferase 1 Inhibitor (DNMT1), die Aktivierung verschiedener 
Tumorsuppressorgene via passiver Demethylierung inhibiert. 5-AZA ist ein 
bekanntes epigenetisch wirksames Medikament welches als Reservetherapeutikum 
für die Therapie des HCCs eingesetzt wird. Ebenfalls zeigen neuere Studien, dass 
die aktive Demethylierung, welche durch TET-Proteine katalysiert wird, eine wichtige 
Rolle bei der Kontrolle globaler Methylierungsderegulationen durch Umsetzung von 
5-Methylcytosin (5mC) zu 5-Hydroxymethylcytosin (5hmC) spielt. TET-Proteine sind 
Fe(II)/2-OG-abhängige Dioxygenase deren Funktion durch Vitamin C (L-Ascorbyl-2-
Phosphat)verstärkt wird. Die vorliegende Dissertationsarbeit beschäftigt sich mit der 
Fragestellung, ob 5-AZA eine TET-abhängige aktive Demethylierung in HCC 
Zellenstimulieren kann und ob Vitamin C den Effekt von 5-AZA bezüglich der aktiven 
Demethylierung hervorrufen oder verstärken kann. Ein weiterer Schwerpunkt dieser 
Dissertationsarbeit ist der Einfluss der aktiven Demethylierung auf den Zellzyklus. 
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Des Weiteren steht im Fokus dieser Arbeit der Zusammenhang zwischen 
epigenetischer Modifikation und der Verbesserung der Biotransformation von 
Xenobiotika in HCC. Einige HCC-Zelllinien werden in der pharmazeutischen Industrie 
routinemäßig für Metabolismusstudien eingesetzt. Aufgrund ihrer guten Verfügbarkeit 
sind sie eine attraktive Alternative für primäre humane Hepatozyten, welche 
innerhalb weniger Tag in Kultur dedifferenzieren und somit ihr metabolisches 
Potential rasch verlieren. Viele HCC-Zelllinien zeigen eine sehr geringe metabolische 
Aktivität, da die entsprechenden Biotransformationsgene (CYP450) relativ gering 
exprimiert werden und/oder die Zellen nicht vollständig differenziert sind. Durch 
Verbesserung der metabolischen Aktivität einer HCC-Zelllinie, zum Beispiel durch 
Steigerung der Expression der CYP450-Gene, könnte diese für Studien im Bereich 
der Medikamententwicklung eingesetzt werdenUm die Rolle von 5hmC hinsichtlich 
der HCC-Entstehung besser zu verstehen, wurden verschiedene HCC-Zelllinien 
(Huh-7, HLE, HLF), primäre humane Hepatozyten (pHH) und Gewebe von gesunden 
und an HCC-erkranken Probanden untersucht. 5mhC wurde durch 
Immunohistochemie und Immunofluoreszenz im humanen HCC-Gewebe und in der 
HCC-Zelllinie analysiert. Anschließend wurden die Ergebnisse des humanen HCC-
Gewebes mit den Leberproben von ‚gesundem Gewebe und die der HCC-Zelllinie 
mit  den primären Hepatozyten verglichen. Die Menge an mRNA von IDHs (IDH1, 2) 
und TETs (TET1-3) wurde durch Real-Time PCR bestimmt und auf Proteinebene 
mittels Western Blot bestätigt. Im Vergleich zum gesunden Lebergewebe ist die 
Expression von 5hmC signifikant niedriger, die von 5mC im HCC-Gewebe signifikant 
höher. Dies ließ sich durch den Vergleich der HCC-Zelllinie mit PHH bestätigen. 
Ferner haben wir  den Effekt von 5-AZA auf die aktive Demethylierung und die 
Fähigkeit des TET-Cofaktors Vitamin C in Kombination mit 5-AZA, sowie deren 
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Umsetzung von 5mC zu 5hmC, untersucht. Die HCC-Zelllinien wurden mit 5-AZA (0-
20 µM) und Vitamin C inkubiert. Anschließend wurde die Wirkung dieser Substanzen 
anhand der Viabilität der Zellen (Resazurinumsetzung), der Toxizität (LDH 
Ausschüttung), der Proliferation (PCNA), sowie der 5hmC/5mC Verteilung und der 
Expression verschiedener TET Gene bestimmt. Durchgeführt wurden zudem Knock-
down Experimente der TET-Proteine in HCC-Zelllinien durch siRNA mit und ohne 5-
AZA-Behandlung. Anhand der Knock-down Experimente konnten wir zum ersten Mal 
zeigen, dass 5-AZA sowohl die TET-abhängige aktive Demethylierung als auch das 
5hmC/5mC Verhältnis in HCC-Zelllinien und in humanen primären Hepatozyten 
fördert. Darüber hinaus demonstrierten wir, dass Vitamin C als  Kofaktor von TET, 
den Effekt von 5-AZA auf die Umwandlung von 5mC zu 5hmC durch Induktion der 
TET2- und TET3-Genexpression positiv beeinflusst. 
Um den Signalweg des Zellzyklus in Abhängigkeit von Vitamin C und 5-AZA zu 
ermitteln, haben wir die mRNA-Expression von GADD45 und P21 (Real-Time PCR), 
Snail, GADD45, P21 und Cyclin-b-Protein (Western Blot) untersucht. Hier konnten 
wir zum ersten Mal nachweisen, dass die Behandlung von HCC Zelllinien mit einer 
Kombination von 5-AZA und Vitamin C zu einer Verbesserung der Downregulation 
der Snail-Expression, eines wichtigen Transkriptionsfaktors in EMT-Prozessen und 
zu einem Zellzyklusarrest führt. Die kombinierte Behandlung führt außerdem zu einer 
Erhöhung der GADD45-Expression welches das Gleichgewicht zwischen DNA-
Reparatur, Apoptose, Seneszenz und Zellzyklusarrest beeinflusst. 
Schließlich wurde der Effekt von 5-AZA und Vitamin C auf die 
Biotransformationsaktivität (Phase I und II) in HCC-Zelllinien durch die Messung der 
Enzymaktivität und Expression relevanter Gene analysiert. HCC-Zellen, die sowohl 
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mit Vitamin C als auch mit 5-AZA stimuliert wurden, haben eine erhöhte Aktivität von 
CYP450-Enzymen (z.B. CYP1A1 und CYP3A4) welche im Fremdstoffmetabolismus 
eine wichtige Rolle spielen. Diesbezüglich sind jedoch weitere Studien nötig, um die 
Effektivität dieser (5-AZA und Vitamin C) und anderer epigenetischer Substanzen  in 
HCC-Zelllinien zu optimieren. 
Unsere Ergebnisse zeigen deutlich, dass die Expression und die Aktivität von TET2 
und TET3, jedoch nicht von TET1, im hepatozellulärem Karzinom beeinträchtigt sind, 
was zur Reduktion von 5hmC in HCC führt. Außerdem zeigt diese Dissertationsarbeit 
eine neue Funktion von 5-Azacytidin. 5-Azacytidin verbessert durch seine 
Auswirkung auf die TET-Proteine die Bildung von 5hmC, welches in Anwesenheit 
von Vitamin C noch gesteigert werden konnte.  
Dies hat besondere Bedeutung weil Aktive Demethylierung Snail-
Transkriptionsfaktoren inhibiert und die GADD45 Expression in HCC-Zelllinien 
verbessert. Die Wirkung von 5-AZA und Vitamin C auf den Zellzyklus beruht auf der 
Erhöhung der P21-Expression als Folge der Snail-Downregulation und der Induktion 
von GADD45-Expression. Die in dieser Arbeit gezeigten Ergebnisse, könnten die 
Grundlage für neue epigenetische Behandlungsstrategien von HCC darstellen. Die 
vorliegende Dissertationsarbeit verdeutlicht zudem, dass die Erhöhung der 
Biotransformationsaktivität in HCC - Zelllinien durch epigenetische Modifikation 
mittels Anwendung von 5-AZA und Vitamin C möglicherweise dazu führen kann, 
dass HCC-Zelllinien eine vielversprechende Alternative für humane primäre 
Hepatozyten im Medikamentenentwicklungsprozess darstellen könnten. 
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Summary 
Hepatocellular carcinoma (HCC) is one of the most aggressive and prevalent form of 
human malignancies globally and represents the third lethal cancer worldwide due to 
poor prognosis and lack of treatment options. This thesis highlights the urgent 
demand for a new strategy to achieve early diagnosis and effective treatment of HCC 
patients. Global deregulation of methylation is one of the crucial causes of HCC 
affecting essential gene expression at the transcriptional level. 
It has been reported that the anti-cancer drug 5-Azacytidine (5-AZA) mediates the 
activation of tumor suppressor genes through passive demethylation by inhibiting 
DNMT1. 5-AZA is one of the most frequently used epigenetic drugs for cancer 
therapy including for HCC. Recent evidence suggests that active demethylation 
which is mediated by TET proteins may be an important mechanism to control global 
deregulation of methylation by converting 5-methylcytosine (5mC) to 5-
hydroxymethylcytosine (5hmC). TET proteins are Fe(II)/2-OG-dioxygenases 
dependent. Vitamin C (L-Ascorbyl-2-phosphate) has a crucial role in maintaining the 
catalytic activity of Fe(II) 2-OG-dependent dioxygenases which can promote TETs 
activity by enhancing 5mC to 5hmC transition. The goal of this study was to 
investigate whether 5-AZA could trigger an active demethylation in form of the TET-
dependent process in HCC, and whether Vitamin C can induce the effect of 5-AZA 
on active demethylation pattern. Another focus of the study was also to evaluate the 
influence of active demethylation on cell cycle arrest  
Moreover this study explored the relation between epigenetic modification and 
Xenobiotic Biotransformation capacity in HCC cell lines. HCC cell line serves as an 
easy alternative for primary human hepatocytes, due to their high availability for 
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development studies. However, HCCs usually have low metabolic activity due to a 
reduced level of drug biotransformation genes (CYP450). Thus, improving metabolic 
activity of HCC lines, i.e. elevating the level of CYP450 genes, would allow using 
them for drug development studies. This can be achieved by epigenetic changes 
through alteration of the DNA methylation status affecting gene expression of 
CYP450.  
To investigate the role of 5hmC in the development of hepatocellular carcinoma, 
HCC cell lines (Huh-7, HLE, HLF), primary human hepatocytes (PHH), and tissue 
from both healthy and HCC patients (55 patients) were included in this study. The 
presence of 5hmC was determined by immunohistochemical and immunofluorescent 
staining in human HCC tissue and HCC cell lines and then compared with the 
adjacent liver tissue samples and primary hepatocytes, respectively. The mRNA level 
of IDHs (IDH1, 2) and TETs (TET1-3) were studied via real-time PCR and confirmed 
by Western Blot. Expression of 5hmC was significantly lower and 5mC was 
significantly higher in HCC tissue as compared to in the corresponding tumor-free 
liver samples. This finding was confirmed by comparing HCC cell lines to PHH. 
Expression of IDH1, IDH2, TET2 and TET3 was also significantly lower in HCC tissue 
and HCC cell lines than in non-tumor liver tissue and PHH. 
The effect of 5-AZA on active demethylation pattern in DNA was not studied. Instead, 
the effect of 5-AZA on active demethylation and if and to what extent Vitamin C (as a 
TET cofactor) combined with 5-AZA can facilitate the 5mC-5hmC transition were 
investigated in this study. HCC cell lines were stimulated with 5-AZA (0-20 µM) and 
Vitamin C. The effect of these treatments was investigated with regard to viability 
(Resazurin conversion), toxicity (LDH release), proliferation (PCNA), 5hmC/5mC 
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distribution and TET expression. Knock-down experiments on TET proteins in HCC 
cell lines using siRNAs in the presence and absence of 5-AZA were performed. We 
showed here for the first time applying knock-down experiments that 5-AZA is able to 
trigger an active TET2-dependent demethylation process with concomitant significant 
changes in 5hmC/5mC in HCC cell lines and human primary hepatocytes.  
We showed that Vitamin C as a cofactor for TET activity facilitates the effect of 5-AZA 
on the conversion of 5mC to 5hmC by an induction of TET2 and TET3 gene 
expression.  
To understand the signaling pathways, especially cell cycling related signaling 
affected by Vitamin C and 5-AZA, we investigated GADD45 and P21 mRNA 
expression (Real-Time PCR), Snail, GADD45, P21 and cyclin B protein expression 
(Western Blot). We have shown for the first time in HCC that the combination of 5-
AZA and Vitamin C leads to an enhanced downregulation of Snail expression, a key 
transcription factor governing EMT process and cell cycle arrest. The combined 
treatment leads to an increase in GADD45 expression. GADD45 has a key role in 
cell fate by controlling the balance between DNA repair, apoptosis, senescence and 
cell cycle arrest.  
Finally, the effect of the 5-AZA and Vitamin C on the drug biotransformation activity 
(phase I and II) of HCC cell lines was investigated through enzyme activity 
measurement and related gene expression. In HCC cells treated with Vitamin C 
combined with 5-AZA, the increase in the level of some important CYP450 enzymes 
such as CYP1A1, CYP3A4 was observed. Here, further investigation is warranted. 5-
AZA and Vitamin C increase the ammonia detoxification capacity of HCC cell lines.  
 Summary 
 
VIII 
 
As conclusion, our data clearly indicates that the expression and activity of TET2 and 
TET3 proteins but not TET1 are impaired in hepatocellular carcinoma leading to the 
reduction of 5hmC in HCCs. Furthermore, this study identified a novel function of 5-
Azacytidine in promoting a TET-mediated generation of 5hmC which is increased by 
combining 5-AZA with Vitamin C. Active demethylation leads to inhibition of Snail 
transcriptional factor and enhancement of GADD45 in HCC cell lines. An increase in 
P21 expression as a consequence of downregulation of Snail accompanied by the 
induction of GADD45 expression are the main mechanisms leading to cell cycle 
arrest in HCCs by applying the combination of 5-AZA and Vitamin C. These findings 
may open new therapeutic strategies for epigenetic drugs to treat HCC. Finally this 
study exhibited that the increase of drug biotransformation activity in HCC cell lines 
through modification of the epigenetic status by applying 5-AZA and Vitamin C may 
provide HCC cell lines as a promising alternative for human primary hepatocytes in 
drug discovery investigations. 
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1 Introduction 
1.1 Hepatocellular Carcinoma 
Hepatocellular carcinoma (HCC) is one of the most predominant types of primary 
liver malignancy with high rates of mortality worldwide [de Lope et al., 2012]. 
Dramatically, over the past few decades incidence rates of HCC have been 
continuously increasing in the West [Cucchetti et al., 2012; Siegel et al., 2013].  
Although it is the 6th most frequently diagnosed types of cancer, it is the 3rd cause of 
cancer-related deaths with approximately 700,000 deaths per year due to its poor 
prognosis and recurrence of tumors after therapy [Ferlay et al., 2010; Yang & 
Roberts, 2010]. There exist geographic variations of HCC occurrence all over the 
world. Although the majority of cases occur in Asia and Africa, the rate of HCC 
incidence is increasing in developed countries such as USA and UK [Dhanasekaran 
et al., 2012]. Also, a male predominance in the occurrence of HCC is noted with two 
to four times as many men as women suffering from this disease [Jemal et al., 2011]. 
1.1.1 Etiologies of hepatocellular carcinoma 
The etiology of hepatocellular carcinoma consists of various risk factors including: 
chronic infection with HBV and HCV (more than 50% of all cases), chronic alcohol 
abuse (the major cause of liver cirrhosis), food contamination with aflatoxin B1, 
tobacco use, obesity, diabetes, non-alcoholic fatty liver disease (NAFLD) and finally 
certain metabolic disorders such as hereditary hemochromatosis [Anestopoulos et 
al., 2015; Bruix & Sherman, 2011] (Fig.1.1). In addition, there is a correlation 
between the geographic region and the cause of HCC, for example the majority 
causes of HCC in Eastern Asia and Africa are due to HBV and HCV infections while 
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alcoholic cirrhosis and obesity are the major risk factors of most of the Western 
countries [El–Serag & Rudolph, 2007]. 
   
Figure 1.1. Risk factors for developing hepatocellular carcinoma. 
The causative factors associated with HCC development are depicted. Various factors 
including HCV, HBC, Alcohol abuse, Obesity and Diabetes leads to progression of HCC. 
Abbreviations: HCV, hepatitis C, HBV, hepatitis B, HCC, hepatocellular carcinoma, 
NAFLD and nonalcoholic fatty liver disease. 
 
1.1.2 Pathogenesis of hepatocellular carcinoma 
The aforementioned risk factors cause liver injury which is followed by repair and 
regeneration of the damaged tissue by steady proliferation of several cell types of the 
liver resulting in shortening of the telomere and cell damage [Farazi & DePinho, 
2006]. In addition, the hepatic stellate cells (HSC) differentiate into myofibroblasts 
after chronic liver injury and contribute to the fibrotic scar by secreting excessive and 
abnormal collagen in the injured and regenerating liver. Unattended fibrosis, leads to 
the  formation of abnormal islands of regenerating liver nodules surrounded by 
fibrotic scar tissue, which is termed as liver cirrhosis [Seki & Schwabe, 2015]. 
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Molecular mechanisms involved in the development of HCC are variable due to the 
variety of HCC etiology. Thus in HCC, both genetic and epigenetic alterations lead to 
tumor progression [Puszyk et al., 2013]. For instance, in HCC caused by aflatoxin, 
HBV and HCV, the tumor suppressor p53 mutation or inactivation is a common 
characteristic [Hussain et al., 2007]. In alcohol and HCV induced HCCs, liver 
cirrhosis and related micro environmental alteration can be seen [Farazi & DePinho, 
2006]. Inflammation and necrosis are a frequent consequences of alcohol abuse, 
HBV and HCV (reviewed in [Farazi & DePinho, 2006]). Altogether, frequent risk factor 
exposure, life style and environment may lead to aberrant epigenetic status of HCCs 
[Herceg & Paliwal, 2011] (Fig.1.2 A).  
The accumulation of epigenetic modifications such as DNA global hypermethylation, 
telomere shortening, inhibition of DNA damage response pathways, and 
chromosome segregation defects leads to increased genomic instability. The 
genomic instability provokes pre-malignant lesions progression into dysplastic 
nodules with autonomous growth capability [Farazi & DePinho, 2006; Hanahan & 
Weinberg, 2011]. 
As mentioned before, various pathways are implicated in HCC development. For 
example: ErBb receptor family, c-MET receptor and Wnt signaling pathways are 
dysregulated in HCCs. However, aberrant methylation patterns in different promoters 
of some cancer related genes such as E-cadherin, COX2 and p16INK4a  indicate the 
important role of epigenetics in HCC progression [Farazi & Depinho, 2009]. It was 
shown that a large number of genetic or epigenetic modifications of critical 
oncogenes or tumor suppressor genes result in diverse malignant phenotypes of 
cancer cells [Liu et al., 2014a]. Therefore, linking the hallmarks of HCC with genetics 
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and epigenetics may lead to a new strategy to identify promising targets for HCC 
therapy. Various cancer hallmarks and the underlying molecular changes during 
HCC progression are summarized in (Fig.1.2B). 
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Figure 1.2. Molecular pathways, genetic and epigenetic contributions to HCC 
progression. 
A)  Frequent exposure to risk factors, life style and environment changes may lead to 
aberrant genetic and epigenetic status of HCCs (modified from [Farazi & Depinho, 2009]) 
B) Multiple cancer hallmarks are involved in HCC progression including sustained cell 
proliferation, evading growth suppressors, resistant to cell death, invasion, metastasis, 
angiogenesis and deregulated energy metabolism. Molecular alterations including 
overexpression of oncogenes, hypermethylation or mutation of tumor suppressor genes, 
activation of stem cells and infiltration of the immune system lead to malignant 
transformation of HCC [Liu et al., 2014a]. 
 
A 
B 
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1.2 Epigenetics and HCC  
Epigenetics is defined as a permanent change of gene expression or phenotypes 
during cell proliferation and development, which does not cause a change of the DNA 
sequences [Dupont et al., 2009]. Epigenetic modification can be passed through cell 
division to daughter cells in order to preserve ‘cellular memory’ therefore it is 
heritable from parent to offspring [Egger et al., 2004]. Epigenetic regulation takes 
place at three separate stages: 1) nucleosome positioning, 2) histone modification, 
and 3) DNA methylation (Fig.1.3) [Portela & Esteller, 2010]. Chromatin complexes 
and non-coding RNAs together with aforementioned factors determine the chromatin 
structure (heterochromatin/euchromatin formation). Epigenetics has a significant role 
in a variety of cellular processes, cellular differentiation, maintenance of cell memory 
and aging [Delcuve et al., 2009]. Aberrant epigenetic modification leads to repression 
of some particular cellular genes and genomic instability which may cause oncogenic 
transformation and heterogeneity in human malignancies including HCC [Herceg, 
2007; Herceg & Paliwal, 2011; Tanaka et al., 2002]. Therefore, the field of 
epigenetics has been attracting increasing attention for cancer therapy in recent 
years. 
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Figure 1.3. Epigenetic machinery and interplay between epigenetic factors. 
Epigenetic regulation depends on the three following epigenetic factors: DNA methylation, 
histone modification, and nucleosome positioning. The interaction between these factors 
results in the final outcome but disturbances of this balance lead to several diseases 
[Sajadian & Nussler, 2015]. Abbreviations: DNMT: DNA Methyl Transferase, HAT: Histone 
Acetylation Transferase, HDAC: Histone Deacetylase, HMT: Histone Methyltransferase, 
HDM: Histone Demethyl Transferase  
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1.2.1 DNA methylation 
DNA methylation has been attracting increasing attention in the past years and it 
plays an important role in gene regulation, particularly at the CpG site of eukaryote’s 
DNA [Herceg & Paliwal, 2011]. DNA methylation plays an important role in different 
cellular processes, especially in the inactivation of the X-chromosome, in silencing of 
the retrotransposon (known as repetitive elements), and in the regulation of gene 
expression [Laird, 2003].  
During the DNA methylation process, a methyl group (CH3) is attached to the phenyl 
ring of the cytosine at the 5 carbon position yielding 5-methylcytosine (5mC). Somatic 
cell methylation can take place at all CpG (cytosine-phosphate-guanine) dinucleotide 
positions except at the CpG Island [Suzuki & Bird, 2008]. CpG islands are parts of 
the DNA with more than 500 bp and over 55% of GC content and accommodate 
approximately 60% of the mammalian gene promoters [Takai & Jones, 2002]. When 
DNA methylation occurs in these promoters, some crucial transcription factors (TF) 
are down-regulated with subsequent inhibition of the corresponding protein 
formation. Furthermore, it has been proven that even in regions that are poor in 
CpGs, such as the promoter of Oct4 gene , DNA methylation plays an important role 
in gene regulation [Das & Singal, 2004]. DNA methylation is catalyzed by a family of 
enzymes, referred to as DNA methyltransferases (DNMTs). Up to now, the following 
DNMTs have been discovered: DNMT1, DNMT1b, DNMT1o, DNMT1p, DNMT2, 
DNMT3A, DNMT3B, and DNMT3L [Das & Singal, 2004]. 
DNMTs such as DNMT3A, DNMT3B and DNMT3L are apparently responsible for the 
de-novo DNA methylation during the early embryogenesis process [Kareta et al., 
2006]. In order to maintain the methylation in daughter cells, a protein referred to as 
UHRF1 (ubiquitin-like protein with PHD and RING finger domain 1) binds to hemi-
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methylated DNA. During replications, UHRF1 causes DNMT1 to methylate new 
cytosine from synthesized DNA strands. There exists also growing evidence which 
suggests that DNMT3A/B are also involved in maintaining the DNA methylation 
pattern in somatic cells, specifically in imprinted genes and repeated elements  
(Fig.1.4). 
     
Figure 1.4. DNA methylation through de novo and maintenance DNMT enzymes. 
De novo methylation occurs through recruiting DNMT3A and DNMT3B followed by 
maintenance of methylation by replication and including DNMT1. (modified from [Sasaki, 
2005]). 
 
 
The significance of DNMTs was demonstrated in various animal studies, in which it 
has been proven that mice lacking DNMTs died during their early development or 
 Introduction 
 
10 
 
shortly after birth [Blair & Yan, 2012]. Nevertheless, the expression of these enzymes 
differs between various types of cancer and it is not always associated with hyper- or 
hypomethylation, as had been expected. Sometimes, the expression of DNMTs is 
regulated by miRNAs, which may explain the differences in the expression of DNMTs 
in various tumors [Pan et al., 2010]. For instance, it has been demonstrated in 
several studies that DNA demethylase is post-transcriptionally regulated by mir29 
and mir148 [Pan et al., 2010]. Furthermore, So et al. have claimed that DNA 
methyltransferase controls stem cell aging through microRNA. They have shown that 
DNMT inhibition leads to a decrease of the expression of Polycomb groups (PcG) 
and to an increase of the expression of microRNAs (miRNAs) that target PcG [So et 
al., 2011]. 
Although the methylation pathway is the same in mammals and plants, they follow 
different demethylation machinery. In plants, the methyl residue of 5mC is removed 
by DNA glycosylase, leaving an abasic site that is replaced by an unmethylated 
cytosine via base excision repair (BER) [Gong et al., 2002]. In vertebrates, the 
possible pathway to remove 5mC is passive demethylation during replication. 
Passive demethylation takes place through dilution of symmetrically-methylated 
regions by inactivation of DNMT1 (maintenance DNA methyltransferase) after DNA 
replication. This ultimately results in hemimethylation in the daughter cells. 
Consecutive cell division and 5mC dilution leads to generation of two hemimethylated 
and two unmethylated daughter cells [Kagiwada et al., 2013]. Nevertheless, 5mC is 
lost after fertilization in the paternal genome before replication has even started, and 
some non-replicating cells like neurons are demethylated. This pattern suggests the 
existence of an active demethylation [Branco et al., 2012]. 
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1.2.2 DNA demethylation 
In early embryogenesis, many researchers have observed a loss of DNA methylation 
and subsequently have postulated the existence of several DNA demethylases and 
various mechanisms of the DNA demethylation (Fig.1.5) [Kohli & Zhang, 2013; Wu & 
Zhang, 2010]. The potential candidates for active demethylation pathway are ten-
eleven-translocation proteins (TET1, TET2 and TET3), which are named after the 
ten-eleven-translocation (q22, q23) (10, 11) that occurs in rare cases of acute 
myeloid and lymphocytic leukemia [Ito et al., 2010; Tahiliani et al., 2009]. 5mC is 
oxidized by TET proteins and thereby converted to 5-hydroxymethylcytosine (5hmC). 
TET proteins belong to the family of Fe (II)/2-oxoglutarate-dependent dioxygenases 
and they are able to further oxidize 5hmC to 5-formylcytosine (5fC) and 5-
carboxycytosine (5caC) [Ito et al., 2011]. In addition to the conserved catalytic 
domain that is typical of Fe (II)/2-oxoglutarate-dependent dioxygenases in all three 
proteins of the TET family, such as TET1 and TET3 containing a CXXC domain that 
has an affinity for binding to CpG dinucleotides motif, which is involved in the 
recruitment of TET1 and TET3 to the DNA. The CXXC domain of TET2 is separated 
during development and broken down into separated genes that encode IDAX 
(inhibitor of the Dvl and axin complex; also known as CXXC4). It has been reported 
that IDAX, as a Wnt signaling inhibitor, regulates TET2 activity by targeting TET2 for 
destruction via the caspase dependent pathway (reviewed in [Williams et al., 2012]). 
Expression of TET proteins is tissue specific. For instance, TET1 is mainly expressed 
in ESC while TET2 and TET3 are more or less ubiquitous [Globisch et al., 2010]. 
Consequently, there are different levels of 5hmC (but not 5mC) in different tissues. 
The level of 5hmC is relatively high in ESCs, which continuously decreases during 
differentiation into adult cells [Koh et al., 2011; Tahiliani et al., 2009]. 
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Conversion of 5mC to 5hmC takes place either by passive demethylation through 
inhibition of the DNMT1 activity at hydroxymethylated CpGs during replication or by 
active demethylation mechanisms [Valinluck & Sowers, 2007]. One potential active 
demethylation mechanism is further oxidation of 5hmC to 5fC and 5caC by TET 
enzymes [He et al., 2011; Ito et al., 2011]. It was reported that 5fC and 5caC can be 
removed by thymidine DNA glycosylase (TDG), producing an abasic site that is then 
repaired by the base-excision-repair (BER) machinery to cytosine  [He et al., 2011; 
Maiti & Drohat, 2011]. It was also shown that in ESCs, 5caC was converted directly 
to cytosine without BER interference, suggesting direct decarboxylation of 5caC as 
another putative demethylation mechanism. 5hmC could be also be removed via 
deamination machinery by recruiting AID/APOBEC deaminases [He et al., 2011]. It 
was also reported that 5hmC could be deaminated to 5-hydroxyuracil (5hmU) by the 
apoliprotein B mRNA editing enzyme, catalytic polypeptide (APOBEC) and cytidine 
deaminase (AID) followed by TDG [Guo et al., 2011b]. Apparently, multiple pathways 
are involved in the removal of 5mC from the genome and TET proteins play an 
important role in most of them. Different tissues might use different demethylation 
pathways to remove 5mC from the genome [Branco et al., 2012]. However, it was 
also suggested that active demethylation can occur via the GADD45-mediated BER 
and NER pathways. In the BER pathway, 5mC is deaminated to thymidine via AID. 
Subsequently, MBD4 or TDG identify the T:G mismatch in order to remove the base 
site by the BER machinery [Delatte & Fuks, 2013]. 
Altogether, DNA methylation is reversible, either through passive demethylation via 
DNA replication or by active demethylation via DNA repair followed by base excision 
repair of modified nucleotides or DNA glycosidase [Kohli & Zhang, 2013; Tahiliani et 
al., 2009] (Fig1.5). 
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Figure 1.5. Potential pathways for DNA demethylation. 
A) Domain architecture of TET proteins. TET proteins consist of 3 conserved domains 
including CXXC zinc finger domain, the cys-rich region and double strand β-Helix 
(DSBH) fold of 2OG/ Fe (II) dioxygenase domain. B) Genomic 5-methylcytosine (5mC) 
can be removed either passively via replication or by active demethylation pathways 
with 5hmC as intermediate by recruiting TET proteins. Following 5hmC oxidation, 
demethylation occurs by dilution of oxidized bases or by removal through DNA 
glycosidase- and DNA repair-mediated excision of modified (modified from [Kohli & 
Zhang, 2013]). Abbreviations: C) Cytosine, DNMT: DNA methyltransferase, 5mC: 5-
methylcytosine, 5hmC: 5-hydroxymethylcytosine; 5fC: 5-formylcytosine, 5caC: 5-
carboxylcytosine, 5hmU: 5-hydroxymethyluracil, TDG: Thymine DNA Glucosidase, 
BER: Base Excision Repair, APOBEC: Apolipo protein B mRNA editing enzyme 
catalytic peptide (Modified from [Ko et al., 2013; Williams et al., 2012]). 
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1.2.2.1  TET proteins and Vitamin C 
TET enzymes are Fe(II)/2-oxoglutarate (2OG)-dependent dioxygenases [Ito et al., 
2010; Ito et al., 2011; Kohli & Zhang, 2013; Tahiliani et al., 2009]. As described 
before, TET proteins contain catalytic domains consisting of a double strand β-helix 
(DSBH), binding to Fe(II)/2OG, which means they show their activity only in presence 
of Fe(II), and that it is necessary to sustain their state as an electron donor to 
maintain the redox state of Fe. It was shown that Vitamin C reduces the oxidized iron 
species. Therefore, it has a significant role in maintaining the catalytic activity of 
Fe(II)/2OG-dependent dioxygenases and supports the maintenance of the active 
form of TET proteins (Fig1.6). Vitamin C may reduce the requirement of a cofactor in 
TET mediated hydroxylation of 5mC to 5hmC resulting in alteration of the DNA 
methylation status [Monfort & Wutz, 2013]. Recently, it was shown that Vitamin C has 
an important role in reprogramming of somatic cells by regulating TET1 and 
modulating mesenchymal-to-epithelial transition (MET) [Chen et al., 2013a]. 
Therefore, Vitamin C might be an important factor in reducing the risk of promoter 
hypermethylation and in maintaining the 5hmC state [Blaschke et al., 2013; Monfort 
& Wutz, 2013; Yin et al., 2013]. It was also shown that Vitamin C can facilitate the 
differentiation of hematopoietic stem cells by inducing TET2 [Monfort & Wutz, 2013]. 
 
 
 
Figure 1.6. Vitamin C is suggested as an additional cofactor in conversion of 
5mC to 5hmC of TETs. 
Vitamin C can reduce Iron to Fe(II) and restore the catalytic  activity of enzymes 
(modified from [Minor et al., 2013]). 
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1.2.2.2 Role of TET proteins 
TET proteins play different roles in diverse biological processes, including epigenetic 
regulation of gene transcription, embryonic development, stem cell functions, and 
cancer. They mediate the DNA demethylation process and change the epigenetic 
state of DNA. A loss of 5hmC together with a down-regulation or mutation of TET 
proteins has been reported in numerous types of cancer, like melanoma, breast, 
prostate, myeloid, brain, and liver cancer [Lian et al., 2012]. It has been 
demonstrated that in patients suffering from acute myeloid leukemia (AML), TET1 
protein influences mixed lineage leukemia (MLL) development [Wu & Zhang, 2010]. 
Furthermore, several changes in the TET2 protein e.g. deletion and deactivation of 
TET2, have been identified in 30% of all patients suffering from different kinds of 
myeloid malignancies and the majority of the TET2 alterations include single or 
double copy defects and nonsense/frame shift mutations suggesting that TET2 
lesions cause a loss of function [Ko et al., 2013; Li et al., 2011]. Therefore, it has 
been suggested that TET2 is a possible tumor suppressor gene that is responsible 
for myeloid malignancies [Li et al., 2011]. Furthermore, the loss of 5hmC in 
correlation with clinical progression and relapse of melanoma has been reported 
[Lian et al., 2012]. 
1.2.3 DNA methylation and HCC 
Numerous studies have reported that tumor cells exhibit a major disruption in the 
regulation of the DNA methylation pattern in cancer including in HCC (Fig.1.7). 
Therefore, over the last few years, changes in DNA methylation have been 
particularly investigated in various cancer types [Baylin & Herman, 2000]. Earlier 
studies have demonstrated that the hypomethylation of interspersed repetitive DNA 
is a common feature of numerous types of cancer that causes genomic instability and 
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aberrant transcription initiation [Caiafa & Zampieri, 2005]. Recent studies have 
proven that the hypermethylation of focal CpG islands is elevated in cancers and 
may result in inhibition of various miRNAs, tumor suppressor and functional genes 
[Ehrlich, 2002; Esteller, 2002]. However, detailed mechanisms leading to hyper- or 
hypomethylation are far from being clearly understood. 
 
Figure 1.7. DNA methylation in HCC. 
In HCC cells, the pattern of DNA methylation is often altered, resulting in global 
hypomethylation of genome associated with hypermethylation at CpG Island within the 
promoters of critical genes such as tumor suppressors (modified from [Qiu, 2006]). 
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1.2.3.1 DNA hypermethylation and HCC 
CpG islands are protected by various defense mechanisms by accessing the DNA 
methyltransferase, such as DNA replication timing, active demethylation, or active 
transcription. Most genes that are susceptible to hypermethylation are associated 
with the regulation of DNA repair, apoptosis, cell cycle, drug resistance, metastasis, 
and differentiation [Das & Singal, 2004]. Many tumors are hypermethylated in one or 
more genes. For instance, in breast cancer, it has been shown that several critical 
genes, which seem to be important in tumorigenesis, are hypermethylated. Among 
these genes, cell adhesion genes, inhibitors of matrix metalloproteinases as well as 
the estrogen receptor (ER) and progesterone receptor (PR) as steroid receptor 
genes are included and have been linked to breast cancer development [Yang et al., 
2001]. 
Hypermethylation induces inactivation of a wide range of critical genes in HCCs 
which leads to the progression of cancer [Anestopoulos et al., 2015; Mah & Lee, 
2014; Mínguez & Lachenmayer, 2011]. It was reported that DNMT1, DNMT3A and 
DNMT3B are up-regulated in all kinds of liver cancer [Nagai et al., 2003; Oh et al., 
2007]. In addition, it was shown that the tumor suppressor gene p16 (CDKN2A) is 
hypermethylated in most HCCs and that it is related to the progression of cancer 
[Liggett & Sidransky, 1998]. SOCS1 gene (Suppressor of Cytokine Signaling 1) was 
illustrated to be hypermethylated which promotes an endless cell cycle. SPCS1 
(Signal Peptidase Complex Subunit 1) is a negative regulator of the JAK/STAT 
pathway and it is another frequently studied prognostic marker for HCC [Yoshikawa 
et al., 2001]. Promoter methylation of GSTP1 was also reported in HCC with HBV or 
HCV infection and GSTP1 methylation is correlated with age and alcohol intake [Mah 
& Lee, 2014]. GADD45 is another crucial gene which is deregulated in HCC 
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[Gramantieri et al., 2005; Qiu et al., 2004]. Accumulations of a number of evidences 
in recent years implies that GADD45 genes are implicated in various pathways such 
as cell cycle arrest, DNA repair, cell survival, apoptosis and epigenetic modification of 
genes [Cretu et al., 2009] GADD45 is known as a stress sensor, mediating the 
complex interplay of physical interactions with proteins which are responsible for 
stress stimuli and cell cycle regulation including PCNA, P21, Cdc2/Cyclin B, P38 and 
JNK stress response kinases [Cretu et al., 2009; Hall et al., 1995; Harkin et al., 1999; 
Kearsey et al., 1995; Niehrs & Schäfer, 2012; Zerbini & Libermann, 2005]. In 
addition, it was shown that GADD45 has a role in active demethylation associated 
with TDG and MBD4 [Delatte & Fuks, 2013]. Interestingly, it was shown that the 
GADD45 gene is methylated and silenced in HCC which leads to progression of HCC 
[Qiu et al., 2004].  
 
Figure 1.8. GADD45 regulates different pathways. 
This figure shows the regulatory of GADD45 on different pathways (cell cycle, cell 
proliferation, cell survival, apoptosis and demethylation) (modified from [Cretu et al., 
2009]). 
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Another important mechanism affected in HCC is the Cell-Cell-Adhesion and 
Epithelial-Mesenchymal-transition (EMT) during the progression of HCC (Fig.1.8) 
[Kwon et al., 2005]. E-cadherin is a member of the calcium-mediated membrane 
glycoprotein and it is known as an adhesion molecule which is expressed on all 
epithelial cells and plays an important role in the maintenance of cell polarity and 
environment [Sugimachi et al., 2003; Tang et al., 2011]. Through inactivation of E-
cadherin, cells lose their adherent junctions and impairment of cell adhesiveness. 
Therefore, decrease of E-cadherin expression is associated with cell invasion, drug 
resistance, tumor progression and metastasis which are characteristics of tumor cells 
[De Herreros et al., 2010; Lee et al., 2006]. In most types of epithelial cancer, 
alteration of genetic and epigenetic mechanisms leads to down-regulation of E-
cadherin [Tischoff & Tannapfel, 2008] Decrease or loss of E-cadherin expression is 
mainly caused by aberrant CpG island methylation in HCC and it was shown that 
loss of heterozygosity (LOH) of E-cadherin is associated with hypermethylation of 
CpGs [Kwon et al., 2005]. Therefore, modifying the methylation status of DNA in 
cancer cell may lead to reactivation of E-cadherin and inhibits EMT. 
Moreover, it was reported that the transcription factor Snail, a zinc-finger 
transcriptional repressor, directly represses the expression of E-cadherin aiding the 
progression of EMT, especially in epithelial kind of cancers such as HCC [Batlle et 
al., 2000; Sugimachi et al., 2003]. It was shown that the Snail gene is regulated via 
DNA methylation and results in E-cadherin gene inhibition which provokes EMT-MET 
transition in HCC [Chen et al., 2013b]. Snail not only inhibits E-cadherin expression 
during EMT transition but also changes the phenotype of the cells and provokes the 
expression of mesenchymal markers [Wang et al., 2013]. Snail also induces the 
resistance of cells towards cell death by withdrawal of survival factors like PI3K, ERK 
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and inhibition of cell cycle check points like p21 which is known as an inhibitor of cell 
cycle in either G1/S or G2/M phase [Takahashi et al., 2004]. The role of Snail in 
different molecular pathways is summarized in (Fig.1.9). 
 
Figure 1.9. The snail gene is an inducer if cell survival and cell movement. 
Snail gene expression evokes the loss of epithelial marker and gain of mesenchymal 
markers including cells morphology changes with acquisition of motility and invasive 
characteristic (Modified from [Barrallo-Gimeno & Nieto, 2005]).  
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The most important highly methylated tumor related genes in HCC are provided in 
Table 1.1. Taken together, therapeutic agents that can target the methylation status 
of DNA in order to activate the promoters of suppressed genes like tumor suppressor 
genes, open a new avenue of hope for HCC therapy togetherwith other treatments 
such as radiation therapy  
Table 1.1. Promoter methylation of different tumor-related genes in HCCs.  
Gene Function Ref 
P169NK4a CDK inhibitor 
[Lee et al., 2013; 
Suzuki & Nohara, 
2013] 
SOCS1 
Cytokine inhibitor 
(JAK/STAT inhibitor) 
[Yoshikawa et al., 
2001; Zhang et 
al., 2014] 
GSTP1 Detoxification 
[Zhong et al., 
2002] 
CYP24A1/CYP7B1 Drug Biotransformation [Deng et al., 2010] 
CASP8/TMS1/RASSSF1A Apoptosis [Yu et al., 2002] 
MGMT DNA repair 
[Zhang et al., 
2003] 
E-cadherin/M-cadherin/H-
cadherin 
Cell adhesion 
[Ripoli et al., 
2011; Yamada et 
al., 2007; Yu et 
al., 2002] 
hMSH1/hMSH2/hMSH3 Mismatch repair 
[Park et al., 2006; 
Wang et al., 2001] 
P21-P53-RB Tumor suppressor 
[Zhang et al., 
2008] 
GADD45 β DNA damage response 
[Higgs et al., 
2010] 
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1.2.3.2 DNA hypomethylation in HCC 
Hypomethylation is an alteration in DNA methylation which is frequently seen in solid 
tumors [Feinberg & Vogelstein, 1983; Kim et al., 1994; Lin et al., 2001], and is a sign 
of a progressive malignancy [Bedford & Van Helden, 1987]. Furthermore, it has been 
reported that the hypomethylation status contributes to oncogenesis through up-
regulation of some oncogenes, like H-RAS and c-Myc [Feinberg & Vogelstein, 1983], 
as well as by chromosome instability [Tuck-Muller et al., 2000]. Deregulation of a 
methylation state is frequently observed in HCCs. Structural-nuclear function is 
affected by global hypomethylation leading to chromosomal and genomic instability. 
DNA hypomethylation of pericentromeric satellite regions associated with 
overexpression of DNMT3B was reported in HCC which results in chromosomal 
instability [Saito et al., 2002]. 
Nevertheless, aberrations not only occur in the DNA methylation, also in the 
regulation of histone modifications which also leads to cancer development [Dawson 
& Kouzarides, 2012]. For instance, numerous studies have demonstrated that 
histone deacytylases (HDACs) are overexpressed in different types of cancer. This 
overexpression leads to a deacetylation of the Transcription Starting Site (TSS) of 
important genes and subsequently to the assembly of silenced genes into more 
compact structures [Halkidou et al., 2004; Song et al., 2005]. 
In summary, there exists an epigenetic crosstalk between histone modification, 
micro-RNAs and DNA methylation. Post-transcriptionally, miR-29 and miR-148 
regulate the DNA demethylases [Duursma et al., 2008; Fabbri et al., 2007]. 
Moreover, it has been proven that DNMTs interact with HDAC [Yang et al., 2001]. In 
particular, the combination of DNMT and HDAC inhibitors is a primary target for 
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potential therapeutics against cancer [Unoki, 2011; Zhu & Otterson, 2003], because 
these inhibitors are capable of targeting the epigenetic status of DNA and histones 
simultaneously, which may enable the development of more effective anticancer 
drugs. 
1.3 Challenges in HCC management 
One of the major clinical implications in HCC therapy is the poor prognosis of cancer 
at its early stages. Patients are frequently diagnosed at advanced stages, which 
leads to more complicated therapeutic options and a frequently undesired outcome. 
In addition to late diagnosis, HCC is a heterogeneous kind of tumor with 
complications like cirrhosis, HCV or HBV infections; therefore, the management of 
this tumor requires a multidisciplinary approach. Up to date, there are several 
treatment options for HCC including surgical removal of tumor, Chemotherapy, liver 
transplantation and molecularly-based therapeutic such as sorafenib (Nexavar) 
therapy. Sorafenib is a multi-tyrosine kinase inhibitor which affects tumor 
angiogenesis interfering with the vascular endothelial growth factor signaling 
mechanism which is used to treat HCC in advanced stage [Ma et al., 2014; Maluccio 
& Covey, 2012]. Similarly, multiple studies are focused on other drugs targeting other 
molecular growth pathway receptors including: the epidermal growth factor receptor, 
hepatocyte growth factor and platelet derived growth factor receptor [Ma et al., 2014]. 
1.4 Epigenetic drugs and HCC treatment 
In addition to molecular based and conventional therapy, epigenetic drugs provide an 
alternative approach through targeting the methylation status of genes like promoters 
of tumor suppressor genes or reversing histone modifications of altered genes 
(Fig.1.10). 
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Currently, majority of studies focus on the development of epigenetic drugs which 
can reverse the abnormal epigenetic state in cancer to the normal epigenetic state of 
cells. Up to now, the FDA has approved four epigenetic modifying drugs for the 
treatment of cancer: 5-Azacytidine (5-AZA) and 5-Aza-2´-deoxycytidine (5-AZA-dC) 
,DNMT inhibitors, which have been used for patients suffering from myelodyplastic 
syndrome and from acute leukemia, as well as Vorinostat and valporic acid (HDAC 
inhibitors) which are used for treatment of T-cell lymphoma and some hematological 
tumors [Byrd et al., 2005].  
Although 5-AZA and 5-Aza-2´-deoxycytidine have the same therapeutic effect, their 
mode of action in tumor cells is different. It has been demonstrated that 5-Aza-2´-
deoxycytidine is able to induce senescence in tumor cells, while 5-AZA induces cell 
death in tumor cells in vitro and in vivo. These two DNMT inhibitors differ from each 
other on the molecular and the cellular level: For instance, 5-AZA has a ribonuleoside 
structure and can be integrated in both DNA and RNA (20-40% and 60-80% 
respectively), while 5-Aza-2´-deoxycytidine can only be incorporated in DNA. 
Moreover, 5-Aza-2´-deoxycytidine induces more DNA damage and micronuclei 
formation than 5-AZA (Table 1.3) [Venturelli et al., 2013]. 
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Characteristic 5-AZA 5-AZA-dC 
Chemical Structure 
  
DNA/RNA Incorporation RNA & DNA DNA 
Protein Biosynthesis + - 
DNA Strand Break Increase More than 5-AZA 
NK Cell Activity 
Decrease of micronuclei 
formation 
Increase of 
mincronuclei 
formation[Yu et al., 
2002]  
Mechanism 
Inhibits DNMT1 & 
DNMTB 
Inhibits DNMT1 
 
Furthermore, it has been reported that 5-AZA increases the sensitivity of the 
antitumor effects of Docetaxel (DTX) and Cisplation in aggressive and 
chemoresistant prostate cancer [Festuccia et al., 2009]. In addition, it has been 
shown that Pyrazofurin (PF), an inhibitor of orotidylate decarboxylase improved the 
anti-tumor activity of 5-AZA in human leukemia cells [Cadman et al., 1978]. The 
combination of PF and 5-AZA has been suggested being a useful treatment for 
patients who do not respond to standard anti-leukemic therapies [Lancet & Karp, 
Table 1.2. Comparison of 5-AZA and 5-AZA-dC 
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2009]. Furthermore, it has been proven that 5-Aza-2´-deoxycytidine inhibits the 
telomerase activity and reactivates p16 and c-Myc in hepatocellular carcinoma cells 
(HCC), such as the MMC-7721 and the HepG2 cell line [Tao et al., 2012]. 
Other DNMT inhibitors, such as 5-fuoro-2´-deoxycytidine, in combination with other 
drugs are currently undergoing clinical trials for their possible use in treatment of 
different types of cancers [Yang et al., 2010]. The DNA methyltransferase inhibitor 
Zebularin provoked the demethylation of tumor suppressor genes by inducing 
apoptosis, cell cycle regulation in HCC cell lines (Huh7, KMCH, and HepG2), and in 
vivo inhibition of tumor growth in a xenograft model [Nakamura et al., 2013]. 
It has been discussed if the expression of specific DNMT inhibitors might influence 
the differentiation status in developing and dedifferentiating cells. It has been shown 
that 5-AZA improves differentiation in mesenchymal stem cells (MSCs) [Culmes et 
al., 2013; Wakitani et al., 1995; Yan et al., 2014]. Furthermore, we have reported that 
pretreatment of fat-derived old MSCs with 5-AZA improves osteogenic differentiation 
by DNA de-methylation. We have observed a reduction of 5hmC in Ad-MSCs of older 
donors (> 60 years) compared to young donors (< 45 years). After stimulation of cells 
with 5-AZA the osteogenic potential of the cells improved significantly. This was 
further substantiated by an improvement of AP activity and matrix mineralization with 
a concomitant increase of 5hmC as well as with the expression of TET2 and TET3 
[Yan et al., 2014]. Therefore, we have concluded that 5-AZA induce the rejuvenating 
process of older Ad-MSCs through alteration of pluripotency genes like Oct4 and 
Nanog. Furthermore, it has been shown that the incubation of human bone marrow 
MSCs with 1 µM TSA which have been pre-treated with hepatogenic-stimulating 
agents, improves the hepatogenic differentiation of these cells [Snykers et al., 2007]. 
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Moreover, a combination of TSA and 5-Aza-dc has improved the differentiation of 
human CD34+ to CD34/CD90 cells [Milhem et al., 2004]. From our studies, we 
conclude that drugs that modify the DNA or histone methylation also induce changes 
in the pluripotency [Culmes et al., 2013; Yan et al., 2014]. 
1.4.1 Other epigenetic drugs  
In the past years, many anticancer drugs which target the acetylation or methylation 
status of histones through different mechanisms have been developed (Fig.1.10), 
such as HDAC inhibitors of class I, II, III (Sirtuins), IV, HATs, HMTs, HDMs and 
various kinds of kinases. Based on their chemical properties, the HDACs are 
branched into the four following groups: hydroxamic acid, short fatty acids, cyclic 
peptide and benzamide enzymes [Rodríguez-Paredes & Esteller, 2011a]. HDACs 
inhibitors mainly arrest the cell cycle in G1 and G2-M phases, which in turn, induces 
apoptosis and cell differentiation. However, they are able to inhibit angiogenesis and 
metastasis, and to decrease the resistance of tumor cells to chemotherapy [Joseph 
et al., 2004]. Recently, a new epigenetic drug called, Suberoylanilide hydroxamic 
acid (SAHA) has been approved for treating T-cell cutaneous lymphoma by the 
Federal Drug Administration (FDA) [Duvic et al., 2007]. Furthermore, a large number 
of HDAC inhibitors, like e.g. TSA (Tricostatin A), PXD101 (Belinostat), and LBH589 
(Panobinostat), are currently being developed and are undergoing clinical trials 
[Cang et al., 2009; Khan & La Thangue, 2011]. 
Class III HDACs, so called Sirtuins (SIRT) are important for the regulation of 
senescence, survival, and cell proliferation. An increasing number of effective SIRT 
inhibitors have recently been generated [Rodríguez-Paredes & Esteller, 2011b]. 
SIRT1 and SIRT2 inhibitors are likely to stop p53 activity, thereby inducing growth 
arrest in cancer cells and increasing sensitivity of tumor cells towards anticancer 
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drugs [Bitterman et al., 2002]. Salermide, another SIRT1 and SIRT2 inhibitor, 
induces p-53-independent apoptosis in tumor cells and reactivates proapoptotic 
genes by deacytelation of H4K16Ac at the epigenetic level which is mediated by 
SIRT1[Lara et al., 2008]. 
Furthermore, it has been shown that curcumin, garcinol, and anacaridic acid may act 
as HAT inhibitors with an anti-cancer effect in ovarian and colon cancer. It has been 
demonstrated that all three substances are able to inhibit dose-dependently EP300-
mediated p53 acetylation [Mukhopadhyay et al., 2002; Shishodia et al., 2005]. 
DZNep, Chaetocin, and BIX-01294 are known to be lysine HMT inhibitors. It has 
been shown that DZNep promotes apoptosis in the MCF7 cell line (breast cancer) 
and in the HCT116 cell line (colorectal cancer) [Tan et al., 2007]. Chaetocine has an 
anti-cancer effect on multiple myeloma (MM) [Greiner et al., 2005]. BIX-01294 
deactivates the histone H3 lysine 9 (H3K9) methyltransferases G9a and G9a-like 
protein by promoting the apoptotic cell death [Choi et al., 2013]. It has been 
demonstrated that BIX-01294 induces endothelial differentiation in Ad-MSCs. We 
have been able to demonstrate that BIX modifies DNA and histone methylation and 
remarkably increases the expression of various endothelial markers that are required 
for blood vessel formation, such as VCAM-1, PECAM, VEGFR-2, and PDGF [Culmes 
et al., 2013].  
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Figure 1.10. Epigenetic drugs for cancer therapy.  
This figure illustrates some of the most important epigenetic drugs, which are classified in 
relation to their epigenetic target. Abbreviations: DNMT1: DNA Methyltransferase 1, 
HDAC: Histone Deacetylase, PcG: Polycomb Group, Me: Methylated, HAT: Histone 
Acetylase [Sajadian & Nussler, 2015] 
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1.5 Combination of current therapies with epigenetic drugs for HCC 
Combination of epigenetic drugs along with other conventional or molecular based 
therapies may offer an alternative promising tool for cancer therapy. Epigenetic drugs 
can provoke host immunogenicity through induction of antigen presentation. It was 
shown that 5-AZA- 2’-deoxycitide improves CTA, a cancer testis antigen leading to 
increased sensitivity of cancer cells to immunotherapy. The immune-modulatory 
activity of 5- AZA-2’-deoxycytidine, offers a novel strategy for chemo immunotherapy 
for cancers which are resistant to adoptive cell transfer therapy like Melanoma. 
Similarly, it can be useful for treatment of HCCs with inflammatory or HBV/ HCV 
background where increase of IL6 and TNF- are reported. The various conventional 
and molecular based therapies dependent on the stage of tumor are illustrated in 
Fig1.11. 
 
Figure 1.11. Different strategy for HCC therapy dependent of the tumor stages base 
on BS  
This figure shows the different strategy for treatment of HCC dependent of the tumor 
stage; treatment such as liver transplantation, sorafenib and TACE [Granito & Bolondi, 
2009]. 
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1.6 Linking of epigenetic modification and metabolic activity in Hepatoma cell 
lines 
It was shown that the most important hepatic genes are influenced by epigenetic 
regulators such as HDACi and DNMTi [Snykers et al., 2009]. HDACi promotes 
growth arrest and upregulates C/EBPa, HNF-1a, HNF-3a, HNF-3b and HNF-4a 
levels in various hepatoma cells which leads to the increase of CYPs expression 
[Yamashita et al., 2003] and ALB secretion. Therefore, modifying and triggering the 
epigenetic state of hepatoma cell line may induce the CYPs activity by altering the 
expression of genes responsible for CYPs activity. A number of studies focused on 
the effect of DNMTi such as 5-AZA and 5-AZA-dC on the expression of crucial phase 
1 and 2 biotransformation genes and some of these studies indicated the 
improvement of CYP3A4, CYP3A7, CYP1B, UGT2B15 and GSTP1 gene expression 
[Snykers et al., 2009] Therefore, in this study, we investigated the effects of the 
epigenetic modifiers 5-AZA and Vitamin C as a single or a combination treatment on 
improvement of drug biotransformation by modifying the expression of important 
genes such as CYPs (CYP1A1, CYP3A4, CYP2E1, CYP2C9), UGT and GST in 
Hepatoma cell lines (Huh7, HLE, HepG2 and AKN1) and thereby improving their 
function. 
Drug metabolism in the liver can be divided into three phases. In Phase I a functional 
group (e.g., OH, SH or NH2) is added to the substrate and it is characterized by 
oxidative, reductive, and hydrolytic pathways. In phase II, the newly introduced 
functional group is altered to O- and N-glucuronides, sulfate esters, various α-
carboxyamides, and glutathionyl adducts and the polarity relative to the unconjugated 
molecules also increased [Parkinson, 2001]. This two-step transformation should 
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make the substrates more water soluble, so that they can be more readily excreted, 
and result in detoxification.  
There are at least 57 isoforms of CYPs identified in the human liver [Xu et al, 2005]. 
Among these isoforms, CYP3A4 is known to play the important role in drug 
metabolism and is responsible for the metabolism of a large number of clinically used 
drugs. It is therefore an enzyme of interest for the study of drug metabolism 
processes in humans, and is particularly relevant to clinical and drug discovery 
research [Chiang et al., 2014]. 
Therefore, PHH are widely used in drug discovery to study the drug metabolism due 
to their major role in metabolism of drugs according to their cytochromeP450 enzyme 
activity. However, using PHH has limitations of the scarce availability of fresh human 
liver samples suitable for research, complicated isolation procedures, high inter-
individual variability and costs associated with their use. Indeed, isolated hepatocytes  
cultured in a two dimensional technique loosing quickly many liver-specific functions 
including cytochromesP450 (CYP450) genes and their activity [Gomez-Lechon et al., 
2008].  
As an alternative, hepatocytes from animals (rodents) are widely used, but the drug 
metabolism properties of these hepatocytes do not always accurately reflect the 
same drug metabolism as human hepatocytes because of species difference [Chiang 
et al., 2014]. Therefore, human hepatoma cell lines are convenient and reliable 
alternatives to PHH. However, their drug-metabolizing activity is very low in 
comparison with PHH. Many strategies have been used to induce or improve the 
functions of drug-metabolizing enzymes in order to provide more reliable systems: 
For instance, the introduction of cDNAs encoding drug-metabolizing enzymes or 
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growing cells in the presence of dimethyl sulfoxide (DMSO) are used in attempt to 
generate more metabolic competent hepatic cell lines [Gomez-Lechon et al., 2008]. 
In three-dimensional cultures of human hepatoma (e.g. HeparG) an increase in 
mRNA expression of CYP1A1, 1A2, 2B6, 2D6, and 3A4 was observed [Gunness et 
al., 2013]. In addition, the transfection of HepG2 cells with recombinant adenoviruses 
that encode CYP1A2, CYP2C9, and CYP3A4 has been shown to increase the 
activity of these enzymes remarkably to levels comparable to those detected in 
primary human hepatocytes [Tolosa et al., 2012]. Chiang et al., have shown the 
enhancement of CYP3A4 enzyme activity of HNF1α transfected cells [Chiang et al., 
2014]. However, additional studies regarding the use of viral transfection and the 
resulting effect on CYPs expression are needed. 
 
1.7 Aim of the thesis 
The aim of this thesis tries therefore to address the following questions: 
I. What is the correlation of 5hmC and TETs in HCC development? 
II. Does 5-AZA (DNMTi) have a role in active demethylation process? 
III. Does Vitamin C play a role in inducing active demethylation? 
IV. What is the consequence of DNA demethylation in HCCs? 
V. Do 5-AZA and/or Vitamin C improve the metabolic activity of HCC cell lines?
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2 Material and Methods 
2.1  Material 
Device Company 
Auto sampler  Thermo Fisher Scientific GmbH, Dreieich, 
Germany  
Balance KERN ABJ  Kern & Sohn GmbH, Balingen, Germany  
Balance KERN PCB  Kern & Sohn GmbH, Balingen, Germany  
Centrifuge Megafuge 40R  Thermo Fisher Scientific GmbH, Osterode, 
Germany  
Clean Bench Safe 2020  Thermo Fisher Scientific GmbH, 
Langenselbold, Germany  
Digital Monochrome Printer P93DW  Mitsubishi Electric SDN. BHD, Senai, 
Malaysia  
Fluorescence Microscope EVOS-fl  Peqlab Biosysteme GmbH, Erlangen, 
Germany  
FLUOstar Omega  BMG Labtech GmbH, Offenburg, Germany  
LVis Plate  BMG Labtech GmbH, Offenburg, Germany  
Gel Stick Imager  Imaging Instruments GmbH, Chemnitz, 
Germany  
Incubator BINDER  BINDER GmbH, Tuttlingen, Germany  
Step One Plus
TM
 Real-Time PCR System  Thermo Scientific Fisher.Inc, MA, USA 
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Flow Cytometry BD Biosciences. Inc, Heidelberg, Germany 
Ligth Microscope Primo Vert  
Carl Zeiss MicroImaging GmbH, Gottingen, 
Germany  
Microcentrifuge Fresco 17  
Thermo Fisher Scientific GmbH, Osterode, 
Germany  
IPC peristaltic pump  
IDEX Health & Science GmbH, Wertheim, 
Germany  
Power Pack HC  
Bio-Rad Laboratories GmbH, Munich, 
Germany  
Shaker DRS-12  
LTF Labortechnik GmbH & Co. KG, 
Wasserburg, Germany  
Syringe Pump Perfusor Secura  
B-Braun Melsungen AG, Melsungen, 
Germany  
Thermal Cycler Block ARKTIK  
Thermo Fisher Scientific Oy, Vantaa, 
Finland  
Thermal Cycler Block Veriti®  
Applied Biosystems (Life Technologies ™), 
Darmstadt, Germany  
Thermostat Lauda Alpha  
Lauda Dr. R. Wobser GmbH & Co. KG, 
Lauda-Königshofen, Germany  
Vortex mixer LSE™  Corning Incorporated, Corning, USA  
Water bath Aqualine AL25  
Lauda Dr. R. Wobser GmbH & CO. KG, 
Lauda-Königshofen, Germany  
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Product  Company 
Cellstart® Cell Culture Flasks 25, 75 
and 175 cm2  
Greiner Bio-One GmbH, Frickenhausen, 
Germany  
Cellstart® Cell Culture Plates 24,48 and 
96 wells  
Greiner Bio-One GmbH, Frickenhausen, 
Germany  
Falcon® Cell Culture Plates 6 wells  
Becton, Dickinson & Co. Ltd, Franklin 
Lakes, USA  
Cellstart® Tubes 15 and 50 ml  
Greiner Bio-One GmbH, Frickenhausen 
Germany  
Costar® Stripette 5, 10 and 25 ml  Corning Incorporated, Corning, USA  
Cryo Tube™ vials  Nunc, Roslkilde, Denmark  
Pasteur Pipettes 150 mm and 230 mm, 
glass  
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany  
Fixo gum  
Marabu GmbH & Co. KG, Bietigheim-
Bissingen, Germany  
Pipette Tips 10 μl  
Biozym Scientific GmbH, Oldendorf, 
Germany  
Pipette Tips 200 μl  
Sarstedt Aktiengesellschaft & Co., 
Nümbrecht, Germany  
Ratiolab® Pipette Tips 1000 μl  Ratiolab GmbH, Dreieich, Germany  
Rotilabo®-microcentrifuge tubes 1.5 ml  
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany  
Micro Tube 0.5 ml  Sarstedt Aktiengesellschaft & Co., 
Nümbrecht, Germany  
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2.1.1 Chemicals 
Product  Company 
3-(2-(N,N-diethylamino)ethyl)-7-hydroxy-
4-methylcoumarin  
Sigma Aldrich Chemie GmbH, 
Steinheim, Germany  
3-(2-N,N-diethyl-N-methylaminoethyl)-7-
methoxy-4-methylcoumarin  
Sigma Aldrich Chemie GmbH, 
Steinheim, Germany  
3-Cyano-7-hydroxycoumarin  Sigma Aldrich Chemie GmbH, 
Steinheim, Germany  
4-Methylumbelliferone  Sigma Aldrich Chemie GmbH, 
Steinheim, Germany  
5-Carboxyfluorescein  Sigma Aldrich Chemie GmbH, 
Steinheim, Germany  
5(6)-Carboxy-2’,7’-dichlorofluorescein 
diacetate  
Sigma Aldrich Chemie GmbH, 
Steinheim, Germany  
7-Benzyloxy-4(trifluoromethyl)coumarin  Sigma Aldrich Chemie GmbH, 
Steinheim, Germany  
7-Ethoxycoumarin  Fluka Chemie GmbH, Steinheim, 
Germany  
7-Ethoxy-4(trifluoromethyl)coumarin  Sigma Aldrich Chemie GmbH, 
Steinheim, Germany  
7-Hydroxycoumarin  Sigma Aldrich Chemie GmbH, 
Steinheim, Germany  
7-Hydroxy-4(trifluoromethyl)coumarin  Sigma Aldrich Chemie GmbH, 
Steinheim, Germany  
7-Methoxy-4(trifluoromethyl)coumarin  Sigma Aldrich Chemie GmbH, 
Steinheim, Germany  
Acetaminophen  Sigma Aldrich Chemie GmbH, 
Steinheim, Germany  
Acetic acid  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany  
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Acetonitrile  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany  
Agarose  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany  
Ammonium chloride  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany  
Boric acid  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany  
Bovine Serum Albumin (BSA)  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany  
Brij 35  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany  
Bromophenol Blue sodium salt  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany  
Calcium chloride  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany  
Chloroform  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany  
Copper (II) sulphate  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany  
Coumarin  Fluka Chemie GmbH, Steinheim, 
Germany  
D-(+)-glucose  Sigma Aldrich Chemie GmbH, 
Steinheim, Germany  
Diethylpyrocarbonate (DEPC)  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany  
Dibenzylfluorescein  Sigma Aldrich Chemie GmbH, 
Steinheim, Germany  
Dimethylsufoxide (DMSO)  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany  
Ethanol  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany  
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Ethidium bromide  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany  
Ethylendiaminetetraacetic acid disodium 
salt dehydrate (EDTA)  
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany  
Folin & Ciocalteu’s phenol reagent  Sigma Aldrich Chemie GmbH, 
Steinheim, Germany  
Fluorescein  Sigma Aldrich Chemie GmbH, 
Steinheim, Germany  
Glucose oxidase  Sigma Aldrich Chemie GmbH, 
Steinheim, Germany  
Glycerol  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany  
Griseofulvin  Sigma Aldrich Chemie GmbH, 
Steinheim, Germany  
Isopropanol  VWR, Leuven, Belgium  
Magnesium chloride  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany  
Magnesium chloride 25 μM  Axon, Kaiserslautern, Germany  
Monochlorobimane  Sigma Aldrich Chemie GmbH, 
Steinheim, Germany  
Na-K Tartrate  Sigma Aldrich Chemie GmbH, 
Steinheim, Germany  
N-Acetyl-L-Cysteine  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany  
N-(1-naphthyl)ethylenediamine 
dihydrochloride  
Sigma Aldrich Chemie GmbH, 
Steinheim, Germany  
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2.2 Methods 
2.2.1 RNA Isolation  
Cells were treated according to the individual experiments. Culture medium was 
removed and PeqGOLD TriFast (PeQlab, Erlangen, Germany) was added (50 
μl/cm2) to the cells. RNA isolation was carried out according to the Peqlab 
manufacturer’s protocol (Fig.2.1) (https://www.peqlab.de/wcms/de/pdf/30-2010m.pdf 
[19.01.2016]). Then, the cell lysate was scraped off from the culture plate and 
transferred to an Eppendorf tube. The cell lysate was pipetted up and down several 
times for complete breakdown of the cell membrane. After 5 min incubation of TriFast 
cell lysates at RT chloroform was added to the lysate (200 μl/ml TriFast) and mixed 
vigorously for 15 sec. Then, lysates were centrifuged for 15 min at 12,000 g and 
+4°C. The aqueous phase was transferred into a fresh Eppendorf tube. Isopropanol 
was added to the aqueous phase (500 μl/ml TriFast) and mixed by inverting several 
times. The mixtures were incubated at –20°C for 1–2 hrs, then mixtures were 
centrifuged for 10 min at 12,000 g/+4°C. Supernatants were discarded and pellets 
were washed with 1 ml 70% ethanol and centrifuged for 10 min at 12,000g and +4°C. 
Supernatants were again removed carefully and pellets were air dried. Then, the 
pellets were resolved in RNase/DNase free water (0.1% DEPC) and incubated for 20 
min. on ice. Following the final steps RNA samples were frozen at -80°C until further 
use. 
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2.2.1.1 Removal of genomic DNA from RNA preparations  
DNase I is an endonuclease that digest single and double strand DNA. It hydrolyses 
phosphodiester bonds producing mono- and oligodeoxyribonucleotides with 5’-
phosphate and 3’-OH groups. The enzyme activity is Ca2+ dependent and is activated 
by Mg2+ and Mn2+ (https://www.thermofisher.com/order/catalog/product/EN0525 
→ Aqueous phase RNA 
 
→ Interphase DNA  
 
→ Organic phase (Protein, Lipids) 
a) Centrifuge of TriFast and 
sample (15 min 12,000 g 4°C) 
b) Mix Aqueous 
phase with 
isopropanol 
c) Centrifuge 
 (10 min 12,000 g 4°C) 
RNA pellet 
d) Wash RNA pellet 
3x with Ethanol 
Centrifuge 
(10 min 12,000 g 4°C) 
e) Resolve RNA in DEPC 
Figure 2.1. RNA isolation procedure by Trifast 
This figure illustrates the RNA isolation step by using Trifast (from a to e) 
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[19.01.2016]). RNA samples were treated with DNase 1 (Thermo Fisher scientific 
InC, Waltham, MA, USA) like Table (2.1) in RNase–free tube. 
After 30 min incubation at 37°C, 1 µl of 50 mM EDTA was added and incubated for 
10 min at 65°C. In this step RNA hydrolyses during heating with divalent cations in 
absence of chelating agent. The RNA integrity was checked again after removal of 
DNA. 
Components 
Final 
Concentration 
RNA 1-3 µg 
Dnase I 1µl /µg RNA 
10X Reaction buffer 1µl in 10 µl 
DEPC, treated water Up to 20 µL 
2.2.1.2 RNA Quality Check (Quantification and Integrity check) 
TriFast isolates the whole range of RNAs including mRNA and rRNA. The final total 
RNA should be free of DNA and proteins and has a 260/270 ratio of 1.6–2.0. RNA 
was quantified by using the LVis Plate with the omega plate reader at 230 nm, 260 
nm and 280 nm (according to BMG Labtech protocol). After quantification, RNA 
integrity was checked by gel electrophoresis [Green & Sambrook, 2012]. 0.5 μg RNA 
was loaded onto an agarose gel (1.5% agarose in TBE) containing ethidiumbromide 
placed in TBE (90 mM TRIS, 90 mM boric acid and 2 mM EDTA). Gels ran at 90 V 
for 45 min and pictures of the UV induced signal were taken with an INTAS Gel Jet 
Table 2.1. Preparation of DNase I master mix. 
 Material & Methods 
 
43 
 
Imager (INTAS Science Imaging GmbH; Göttingen; Germany). Intact RNA was 
showing two sharp bands representing the 18S and 28S ribosomal RNA. To 
investigate integrity of RNA; samples (0.5 µg/lane) were separated by 
electrophoresis in 1.5% gel (in TBE). Gel ran at 90 V for 45 min: Pictures of Gel was 
taken with GEL-Doc. 
2.2.2 cDNA synthesis and RT-PCR  
Complementary DNA (cDNA) was synthesized by Revert Aid First Strand cDNA 
Synthesis Kit according to manufacturer’s instructor (Cat. Nr: K1612, Thermo Fisher 
scientific.Inc, Waltham, MA, USA). Then, reverse transcriptase PCR (RT-PCR) was 
performed. PCR is used to amplify a specific region of a DNA strand (the DNA 
target). All cDNA samples were diluted to a final concentration of 10 ng/μl. The 
expression of the housekeeping gene GAPDH was checked in all of cDNA samples. 
For PCR, KAPA Tag ready mix PCR Kit was used as a ready-to-use cocktail 
containing all components for PCR, except primers and template. PCR master mix 
was prepared according to manufacturer’s instructor (Peqlab Biotechnology GmbH, 
MA, USA) (Table2.2). 
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Components 
Final 
Concentration 
2X KAPA Taq ReadyMIx 
(1.5 Mm MgCl2 at 1X) 
10 µL 
10 µM Forward Primer 0.5 -2.5 µL 
10 µM Reverse Primer 0.5 -2.5 µL 
DEPC, treated water Up to 20 µL 
Template cDNA As required 
 
After transferring the appropriate volume of PCR master mix, template and primer to 
individual PCR tubes, PCR was performed with the following cycle protocol: 
(Initialization step: 95 C, 5 min, Denaturation Step: 95°C, 30-40s, Annealing step: 
52–65°C, 30–40, Elongation step: 72°C, 30–40 s, Final elongation: 72°C, 5 min. In 
Table 2.3, all used primers are listed with their respective size and annealing 
temperature. The primer annealing temperatures, number of cycles and the amount 
of used cDNA were optimized by testing various conditions. All generated PCR 
products were separated by electrophoresis gel stained with ethidium bromide. Gene 
expression was quantified by the ImageJ 1.45 software (National Institute of Health, 
Maryland, USA). 
 
Table 2.2. Preparation of PCR master mix. 
Initial 
Denaturation 
Denaturation 
Annealing 
Extension 
Final 
Extension 
30-40 s 
1 min/ 
kb 
1 min/ 
kb 
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Gen Forward / Reverse Sequences 
Annealing 
Tm 
Product 
Length 
(bp) 
N of 
Cycle 
cDNA 
(ng) 
DNMT1 
CCGTTTGGTACATCCCCTCC 
CAGGTAGCCCTCCTCGGATA 
62°C 378 35  40  
DNMT3A 
GGCGAGAGCAGAGGACGA 
ATAGATCCCGGTGTTGAGCC 
60°C 157 35 40  
DNMT3b 
AAGTCGAAGGTGCGTCGTG 
AGGACACGGGGTTTTTCCTG 
60°C 262 35 40  
hCYP1A1 
TTCGTCCCCTTCACCATC 
CTGAATTCCACCCGTTGC 
55°C 302 35 40  
hCYP1A2 
TCGACCCTTACAATCAGGTGG 
GCAGGTAGCGAAGGATGGG 
60°C 180 35 
40 
pHH 
20 
hCYP2C9 
CTGGATGAAGGTGGCAATTT 
 AGATGGATAATGCCCCAGAG 
59°C 308 35 
40  
pHH 
20 
hCYP2E1 
GACTGTGGCCGACCTGTT 
ACACGACTGTGCCCTGGG 
59°C 296 35 
40 
pHH 
20 
hCYP3A4 
ATTCAGCAACAAGAACAAGGACA 
TGGTGTTCTCAGGCACAGAT 
56°C 314 35 
40 
pHH 
20 
hCYP3A7 
AATAAGGCACCACCCACCTA 
AGAGCAAACCTCATGCCAAT 
58°C 326 35 
40 
pHH 
20 
hUGT1A6 
CTGCCCGTATGTCCACCT 
GCTCTGGCAGTTGATGAAGTA 
60°C 210 35 
40 
pHH 
20 
hGSTA1 
TCTGCCCGTATGTCCACCT 
GCTCCTCGACGTAGTAGAGAAG
T 
59°C 185 35 
40 
pHH 
20 
Table 2.3. Primer sequences and optimized condition of each primer. 
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hAlbumin 
TTTATGCCCCGGAACTCCTTT 
TGTTTGGCAGACGAAGCCTT 
60°C 142 35 40 
hOTC 
TGGCCCCCGCTGGCTAACTT 
CACGGCCCTTCAGCTGCACTT 
62°C 192 35 40 
hARG 
TGAGAAAGGCTGGTCTGCTTGA
GA 
TGCCAAACTGTGGTCTCCGCC 
62°C 245 35 40 
hASL 
CCCTCAAGCGCAGTGCCCAG 
CTGCACCCACAAACCGGCCA 
62°C 182 35 40 
hASS1 
ACGCCTCCAATCCCAGACGC 
CCCTCCCGCTGGGCGATTTC 
62°C 350 35 40 
hNAGS 
TAACGTGAACCTGCCCGCCG 
TAACGTGAACCTGCCCGCCG 
62°C 224 35 40 
hCPS1 
GGCCATCCATCCTCTGTTGC 
GCTAAGTCCCAGTTCATCCA 
62°C 171 40 40 
hGAPDH 
GTCTCCAACATGCCTCTCTTCAT
CC 
GTCAGTGGTGGACCTGACCT 
56°C 420 35 20 
 
2.2.3 Real Time PCR 
For quantitative real time PCR (qRT-PCR), 40 ng of template cDNA was used for the 
expression level of each target gene (primer sequences are listed in Table 1) using 
SYBR Green qPCR Kit (Thermo Fisher scientific Inc., Waltham, MA, USA) and the 
Step One Plus® Real-Time PCR System (Thermo Fisher scientific, Inc., Waltham, 
MA, USA). Among different existing housekeeping genes (e.g.; GAPDH, ACTB, and 
B2M), B2M was used as an endogenous control because of the constant expression 
of this gene in hepatocellular carcinoma and normal tissue samples. In line with our 
results, Waxman et al. reported the dysregulation of common housekeeping genes 
such as GAPDH and ACTB in hepatocellular carcinoma [Waxman & Wurmbach, 
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2007], which may lead to wrong positive or wrong negative results. Relative 
expression values were calculated from Ct values using the ΔΔCT method with 
untreated cells as a control. Fold induction was calculated according to the formula 
2(Rt-Et)/2(Rn-En) [Saha et al., 2001]. Real-time PCRs were performed as follows: 
denaturation for 10 minutes at 95°C, amplification with 40 cycles and 15 seconds at 
95°C, 40 seconds at 60°C and 15 seconds at 72°C (Step One PlusTM Real-Time PCR 
System, Life technologies, CA, USA). The primer sequences are listed in Table.2.4. 
Each sample was set up in triplicates and the experiment was repeated at least 
twice. 
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Gene Gene bank ID Forward / Reverse Primer 
Product 
length 
(bp) 
TET1 NM_030625.2 
TCTGTTGTTGTGCCTCTGGA 
GCCTTTAAAACTTTGGGCTTC 
77 
TET2 NM_001127208.2 
GAGACGCTGAGGAAATACGG 
TGGTGCCATAAGAGTGGACA 
258 
TET3 NM_001287491.1 
CCCACAAGGACCAGCATAAC 
CCATCTTGTACAGGGGGAGA 
129 
IDH1 NM-001282387.1 
TCCGTCACTTGGTGTGTAGG 
GGCTTGTGAGTGGATGGGTA 
128 
IDH2 NM-002168.3 
TGAACTGCCAGATAATACGGG 
CTGACAGCCCCCACCTC 
121 
Snail NM_005985.3  
ACCACTATGCCGCGCTCTT 
GGTCGTAGGGCTGCTGGAA 
115 
E-cadherin NM_004360.3  
GTCAGTTCAGACTCCAGCCC 
AAATTCACTCTGCCCAGGACG 
254 
P21 NM_001291549.1  
GTCACTGTCTTGTACCCTTGTG 
CGGCGTTTGGAGTGGTAGAAA 
221 
GADD45 NM_015675.3 
GTGTACGAGTCGGCCAAGTT 
GTCACAGCAGAAGGACTGG 
135 
GAPDH NM_002046.4 
TGCACCACCACTGCTTAGC 
GGCATGGACTGTGGTCATGAG 
87 
B2M NM_004048.2 
AGATGAGTATGCCTGCCGTG 
GCGGCATCTTCAAACCTCC 
105 
HPRT NM_000194.2 
CCTGGCGTCGTGATTAGTGA 
CGAGCAAGACGTTCAGTCCT 
137 
 
Table 2.4. The primer sequences used for Real time PCR. 
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2.2.4 Western Blot  
2.2.4.1 Collection of protein lysates  
Cells were treated according to the individual experiments. Culture medium was 
removed and 20 μl/cm2 RIPA lysis buffer (50 mM TRIS, 250 mM NaCl, 2% Nonidet 
P-40, 2.5 mM EDTA, 0.1% SDS, 0.5% DOC, complete protease inhibitors such as 
PMSF, Leupeptide, Aprotinin and 1.0% phosphatase inhibitor: NaF; Na3VO4, pH = 
7.2) was added to the cells, which were scraped from the plate by rubber police-man 
and transferred to an Eppendorf tube and the lysate was vortexed. After incubation 
on ice for 20 min cell debris was centrifuged down (13,000 rpm; 10 min; +4C). 
2.2.4.2 Protein measurement  
Protein concentration was measured in triplicates. Concentrations were determined 
using Micro Lowry Assay method. The concentration of the protein is determined by 
a color change according to the protein concentration. This color change can then be 
measured with photometric techniques by OMEGA plate reader. Procedure was 
done according to the protocol provided by the manufacturer. Standard curves 
ranging from 0-10 μg/μl BSA (triplicate) were included to each measurement. ODs at 
λ = 690 nm were measured by OMEGA plate reader. 
2.2.4.3 SDS-PAGE and Immuno Blotting 
SDS-PAGE was performed on gel made up for cross-linked acrylamide molecules 
am other components. Protein concentration was determined by micro-Lowry and 30-
50 µg of total protein sample were prepared by denaturation of proteins via boiling 
with Lammli buffer containing, ß-Mercaptoethanol and Sodium Docdecyl Sulphate 
(SDS) for degradation, denaturation and providing negative charge of proteins, 
Bromphenol Blue as a tracking dye and Glycerol to minimize diffusion during loading. 
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30-50 µg of total protein was separated by SDS-PAGE and transferred to 
nitrocellulose membranes (Roth GmbH, Karlsruhe, Germany). Electrophoresis 
transfer was used to separate proteins according to their charge (Fig.2.2). After 
transfer the proteins on the blot, blots were stained with Ponceau S solution to 
control proper protein transfer. Then, membranes were blocked by 5% blocking 
buffer [milk powder in Tris buffered saline Tween (TBST)] for 1 hour and incubated 
overnight with TETs, Snail, GADD45α, P21, cyclin B1, E-cadherin and GAPDH 
mouse/rabbit polyclonal primary antibodies at 4°C. The following day, membranes 
were incubated with the corresponding HRP-labeled secondary antibodies for 1 hour 
at RT. Chemiluminescent signals were detected with the ChemoCam (INTAS 
Science Imaging GmbH, Göttingen, Germany) (Fig.2.2) [Mahmood & Yang, 2012].  
The Antibodies details and correlated blocking buffers as well as western blot 
Figure 2.2. Western Blot set up and protein detection method. 
 A) Illustration of Western Blot setup. Transfer sandwich is in the following order: 
Supported Grid (Blue), Soaked Sheets Pads, filtered pad [Whatmann Paper] 
(Pink), Transfer Membrane (yellow) and Gel (Green) B) Protein detection based 
on chemiluminescence is the most sensitive detection methods  .when the 
chemiluminescent substrate combined with the enzyme, produces light as a 
byproduct, which can be captured using CCD camera. 
(www.antibodiesonline.com, www.bio-rad.com [17.01.2016]). 
 
A Western Blot Setup 
B Chemiluminescence 
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condition are provided in Table.2.5. 
 
Antibody 
Company 
and 
catalogue 
No 
 
M.Wt. 
(K.Da) 
Host 
Blocking 
buffer 
Primary 
Ab 
(Dilution) 
Secondary 
Ab 
(Dilution) 
E Cad 
Cell 
signaling    
14472 
135 mouse 
5% Milk in 
0.1% TBST 
1 in 1000 1 in 2000 
Vimentin 
Cell 
signaling      
5741 
57 rabbit 
5% Milk in 
0.1% TBST 
1 in 1000 1 in 2000 
Snail 
Cell 
signaling     
3879 
30 rabbit 
5% Milk in 
0.1% TBST 
1 in 1000 1 in 2000 
GADD45 beta 
Santa Cruz           
SC-33172 
18-27 rabbit 
5% Milk in 
0.1% TBST 
1 in 200 1 in 2000 
N Cad 
Cell 
signaling     
4061 
140 rabbit 
5% Milk in 
0.1% TBST 
1 in 1000 1 in 2000 
Cyclin B1 
Cell 
signaling     
4138 
55 rabbit 
5% Milk in 
0.1% TBST 
1 in 1000 1 in 2000 
P21 WAF1/Cip 
Cell 
signaling     
2947 
21 rabbit 
5% Milk in 
0.1% TBST 
1 in 1000 1 in 2000 
P15/16 
Santa Cruz       
sc-377412 
16 mouse 
5% Milk in 
0.1% TBST 
1 in 200 1 in 2000 
Tet-2 
Sigma 
(SAB35007
11) 
220 rabbit 
5% Milk in 
0.1% TBST 
1 in 1000 1 in 2000 
Tet-3 
Sigma 
(SAB27006
82) 
140 rabbit 
5% Milk in 
0.1% TBST 
1 in 500 1 in 2000 
GADD45 alfa 
Cell 
signaling   
4632 
22 rabbit 
5% Milk in 
0.1% TBST 
1 in 1000 1 in 1000 
Caspase3 
Cell 
signaling     
9662 
17, 19, 
35 
rabbit 
5% Milk in 
0.1% TBST 
1 in 1000 1 in 2000 
cleaved PARP 
Cell 
signaling      
5625 
89 rabbit 
5% Milk in 
0.1% TBST 
1 in 1000 1 in 2000 
Table 2.5. Antibodies details and condition for Western blot. 
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PARP 
Cell 
signaling     
9542 
89, 116 rabbit 
5% Milk in 
0.1% TBST 
1 in 1000 1 in 2000 
GAPDH Sigma 36 rabbit 
5% Milk in 
0.1% TBST 
1 in 5000 1 in 2000 
Beta actin 
Cell 
signaling  
4970 
47 rabbit 
5% Milk in 
0.1% TBST 
1 in 1000 1 in 2000 
2.2.5 Immunofluorescence staining 
Immunostaining of 5hmC and PCNA was performed using a recent published method 
[Szulwach et al., 2011]. Briefly, cells were plated onto cover slips and treated 
according to the experimental setup. After 48 hrs, cells were fixed with 4% 
paraformaldehyde solution for 15 min at RT and then washed with PBS. For 
permeabilization, cells were incubated with 0.5% Triton-X-100 solved in PBS for 15 
min at RT. To denature the DNA only for 5hmC staining, cells were incubated with 
4M HCl for 15 min at RT, rinsed with distilled water and placed in 100 mM Tris-HCL 
(pH=8.5) for 10 min. Cells were rinsed with PBS, then nonspecific binding sites were 
blocked with blocking buffer (10% FCS, 0.1% Tween-20 in PBS) for 1 hour at RT. 
Then, cells were incubated with primary antibodies such as anti-5hmC rabbit 
polyclonal IgG (Active Motif, Inc., CA, USA) or anti-PCNA Rabbit mAB (Abcam plc, 
Cambridge, UK) at 1:1000 and 1:200, respectively in PBS solution containing 1% 
FCS and 0.1% Tween-20 overnight at 4°C. After washing with PBS, cells were 
incubated with secondary antibody solution (ALEXA-Fluor antibodies, Invitrogen. Inc, 
NY, USA), diluted 1:400 in PBS solution containing 1% FCS, 0.1% Tween-20 for 1 
hour at RT. Nuclei were counterstained by incubation with Hoechst 33342 solution (2 
µg/ml in PBS) for 10 min at RT. After a final washing step with PBS, the stained cells 
were mounted with Fluoromount G (Southern Biotech. Inc, NJ, USA). Images of the 
staining were taken with an EVOS fluorescence microscope (AMG, Life technologies, 
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Inc., MA, USA), and analyzed with Image J 1.45s software (NIH, USA) [Polzer et al., 
2010].  
2.2.6 Immunohistochemical staining 
Immunohistochemical stains were performed using 3.5 µm sections of TMA. Slides 
were deparaffinized, dehydrated by rising the sections in Roticlear for 10 min 
following by rinsing them in Ethanol (100% - 90% - 80% - 50%), and after antigen 
retrieval through rinsing and heating the whole slides in sodium citrate buffer (pH:6) 
in microwave with full energy for 5 minutes, the slides were placed in 2N HCL for 
DNA denaturation step for 5hmC/5mC staining for 60 min, rinsed with distilled water, 
and placed in 100 Mm Tris-HCL (pH:8.5) for 10 min. Tissue slides were incubated in 
DAKO Dual Endogenous Enzyme Block (DAKO GmbH, CA, USA) for 10 min. The 
sections were blocked in PBS solution containing 10% FCS and 0.1% Tween-20 for 
1 hour. Section was incubated with either rabbit anti-5hmC at 1:1000 (Active motif, 
39769) or mouse anti-5mC at 1:500 (Active motif, 39649) overnight at 4°C and then 
incubated with ZytoChem Plus HRP One-Step Polymer anti-Mouse/Rabbit/Rat (Cat 
No: ZUC053-006) from Zytomed (Zytomed System GmbH, Berlin, Germany) for 30 
min at RT (100 µl per section). Tissue sections were washed and subsequently DAB 
Substrate Kit High Contrast (Cat: No: DAB 500 Plus) from Zytomed (Zytomed System 
GmbH, Berlin, Germany) was used according to the manufacturer’s instruction. After 
rinsing, the cells were counterstained using a hematoxylin (Carl Roth GmbH, 
Karlsruhe, Germany) for 5 min and immediately rinsed with tap-water. Samples were 
air-dried and mounted with Rotimount and sections were controlled under bright field 
microscope.  
All specimens were evaluated according to the 0-4 grading criteria (based on the 
percentage of 5hmC positive cells) and 0-3 grading criteria (based on the staining 
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intensity) [Liu et al., 2014b]. The intensity was scored from 0 to 3 and defined as 
follows: 0: no staining, 1: weak staining, 2: moderate staining, 3: strong staining 
based on the staining score. In addition, the quick score (Q score) based on 
estimating the percentage (P) of tumor cells showing characteristic staining (0: 
Negative, 1: 10-25%, 2: 25-50%, 3: 50-75% and 4: > 75%) and by estimating the 
intensity (I) of staining was adopted for IHC scoring. The slides were scored by 
multiplying the percentage of positive cells by the intensity (Q = P ×I, maximum = 12). 
The total score was determined from 0 to 12 (http://www.ihcworld.com/ihc-
scoring.htm [03.03.2016]). An overview of the IHC for all tissue sections was 
performed by pathologists (Prof. Dr. Sipos). Two observers evaluated the staining 
results independently and differences in interpretation were resolved by consensus. 
The statistical analysis was performed using the SAS software packages (SAS for 
windows, version 8.0) 
2.2.7 Tissue samples and primary human hepatocyte isolation and cell culture 
condition  
Tissue specimens were obtained from patients undergoing resection of HCC 
according to the approval of local ethics committee. A tissue microarray (TMA) 
contained section of HCC samples and their corresponding noncancerous liver 
tissue.  
Primary human hepatocytes were isolated from human liver tissue according to the 
institutional guidelines from liver resections of tumor patients with primary or 
secondary liver tumor (Ethics approval number: 368/2012BO2). The isolation and 
purification of primary human hepatocytes was performed as previously described 
[Nussler et al., 2009]. Culture conditions of HCC cell lines (Huh7, HLE and HLF) and 
human primary hepatocytes (PHH) were published previously [Dzieran et al., 2013; 
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Lin et al., 2012; Nussler et al., 2009]. HLE and HLF cells were purchased from ATCC 
and Huh7 was purchased from JCRB (Japanese Collection of Research 
Bioresources Cell Bank). The HCC cell as well as PHHs were plated onto collagen 
coated 6, 24, or 96 well tissue culture plates, treated for 24 hrs with different 
concentrations of 5-AZA (20, 10, 5, 1) for 48 hrs. Huh7, HLE and HLF cells were 
cultured in DMEM (Lonza Group Ltd, Cologne, Germany) supplemented with 2 mM 
glutamine (PAA Laboratories GmbH, Pasching, Austria) and 10% FCS (Invitrogen 
GmbH, Darmstadt, Germany) at 37°C and 5% CO2 in a humidified incubator. 
Experiments were conducted between passage numbers 2 and 12 without full 
confluency throughout all experiments. Absence of mycoplasma contamination was 
regularly controlled using a Venor®GeMtest (Minerva Biolabs GmbH, Berlin, 
Germany). 
2.2.8 Cell Viability and Cytotoxicity assay 
2.2.8.1 Resazurin Conversion 
Resazurin conversion is a fluorescence assay which can be used to measure 
proliferation, viability and toxicity (indirectly) in cells. The assay is based on the ability 
of living cells to convert a redox dye (Resazurin) into an end product (resorufin). This 
conversion involves a colorimetric change which can be measured with fluorescence-
based measuring instruments [Nakayama et al., 1997; Nociari et al., 1998]. 
Fluorescence was monitored at an excitation wavelength of 530-560 nm and an 
emission wavelength of 590 nm. The culture mediums were removed from the cells 
and washed twice with DPBS. Then the cells were incubated with 1:10 Resazurin 
stock solution in plain medium in an incubator at 37°C, 5% CO2 for 2 hrs. Wells 
without cells were used as background subtraction from wells with cells. The 
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fluorescence was measured at an excitation wavelength of λ = 544 nm and at an 
emission wavelength of λ = 590-610 nm. The average background was subtracted 
from the florescence intensity of resorufin in cells. 
2.2.8.2 LDH leakage 
Lactose dehydrogenase (LDH) is a cytosolic enzyme present in many different cell 
types. Plasma membrane damage releases LDH into the cell culture media. LDH 
catalyzes the conversion of lactate to pyruvate via NAD+ reduction to NADPH. 
Diaphorase uses NADPH to reduce tetrazolium salt (INT) to red formazan production 
which can be measured at 490 nm. The level of formazan is the indicative of LDH 
release in medium  [Decker & Lohmann-Matthes, 1988]. 
LDH released into cell culture media was measured using a Pierce LDH assay Kit 
(Cat.No: 88953, Thermo Fischer Scientific, Inc., Rockford, USA) according to the 
manufacturer’s protocol. Briefly, cultured cells are incubated with chemical 
component (5-AZA and Vitamin C). 50 l of supernatant transferred into a new plate 
then mixed with 50 l of reaction mixture. After 30 min incubation at room 
temperature, reactions are stopped by adding a stop solution. Absorbance at 490 nm 
and 680 nm is measured using plate-reading spectrophotometer to determine LDH 
activity. Water treated cells are referred as Spontaneous LDH Activity Controls and 
10X Lysis Buffer-treated cells were referred to as Maximum LDH Activity Controls. 
To evaluate LDH activity, the absorbance value of 680 nm (background signal from 
instrument) was substrate from the 490 nm absorbance [(LDH at 490 nm) – (LDH at 
680 nm)].  
Percentage of Cytotoxicity was measured as following: 
 %  𝐶𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦 =  
𝐶𝑜𝑚𝑝𝑜𝑢𝑛𝑑 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝐿𝐷𝐻 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦−𝑆𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠 𝐿𝐷𝐻 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦
𝑀𝑎𝑥𝑖𝑚𝑢𝑚 𝐿𝐷𝐻 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦−𝑆𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠 𝐿𝐷𝐻 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦
× 100 
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2.2.8.3 Flow cytometry based apoptosis and cell cycle detection 
Propidium iodide (PI) flow cytometric assay has been used for the evaluation of 
apoptosis. It is based on the principal that apoptotic cells are characterized by DNA 
fragmentation and loss of nuclear DNA content [Riccardi & Nicoletti, 2006]. PI as a 
fluorochrome binds to DNA and provides a rapid and precise evaluation of cellular 
DNA content and identification of hypodiploid cells by flow cytometric analysis. 
Indeed, DNA analysis is the second important application of flow cytometry. PI has a 
red fluorescence and can be excited at the 488 nm which was determined by flow 
cytometry. PI fluoresces strongly when bounds to DNA, due to the hydrophobic 
nature of the environment. It is possible to identify the proportion of cells that are in 
one of the three interphase stage of the cell-cycle by using PI and measuring their 
relative DNA content by flow cytometry. Cells that are in the G0/G1 phase (before 
DNA synthesis) have a defined amount (2x) of DNA. During S phase (DNA 
synthesis), cells contain between 2x and 4x DNA levels. When cells enter G2 or M 
phases (G2/M), they consist of 4x amount of DNA. (Fig.2.3) [Riccardi & Nicoletti, 
2006]. For flow cytometry analysis, 1*10 6 HCC cells per well were seeded in 6-well 
plates and treated with different concentrations of 5-AZA and Vitamin C. After 48 hrs, 
cells were fixed in 70% of ethanol for at least 1 hour and stained in a hypotonic 
solution with 100 g/ml of RNase and 50 g/ml Propidium Iodide (PI) for 15 min in RT 
[Riccardi & Nicoletti, 2006]. Distribution of cells in the different phases of the cell 
cycle based on the differences in DNA contents was determined by using flow 
cytometer (BD Biosciences. Inc, Heidelberg, Germany). Data were analyzed using 
Modfit software (ModFit LT, Verity Software House, Topsham, USA). 
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2.2.9 Protein depletion by siRNAs  
siRNA transfection was carried out based on Thermo Fisher scientific siRNA protocol 
(www.thermofisher.com/de/de/home/references/protocols/rnai-epigenetics-and-gene-
regulation/sirna-protocol.html). For depletion of TET2 and TET3, the siRNAs were 
ordered from Eurofins MWG Operon (Ebersberg, Germany) and the scrambled 
siRNA for negative control experiments was also obtained from Eurofins. The siRNA 
was transfected with lipofectamine 3000 according to manufacturer’s instructor 
(Invitrogen Inc, Carlsbad, CA, USA). One of the most established method for 
transfection is lipofection in which cationic lipids are used to bring nucleic acid into 
cells [Dalby et al., 2004]. For lipofection, cationic liposomes are used which can 
Figure 2.3. Cell cycle analysis with PI staining by flow cytometry. 
This figure showed the relationship between the cell cycle and the DNA histogram. The 
histogram presents in respect to PI intensity and cell number. This is the typical result for 
untreated healthy cells: most cells are in G1 stage (2N), some cells undergoing DNA 
synthesis (2N–4N) and final population in G2/M stage (4N). 
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easily interact with DNA. These positively charged liposomes interact with negatively 
charged nucleic acids (siRNA) and form stable complexes, so called lipoplexes. Then 
lipoplexes interact with the membrane of the cells and the siRNAs penetrate in to 
cells by fusion of lipoplexes cells followed by repression of the mRNA of specific 
gene and respective protein (Fig.2.4). 
 
Cationic liposome 
siRNA 
Liposome / siRNA 
complex (lipoplex) 
Hydrophilic head 
Hydrophilic Tail 
Figure 2.4. Transfection of the cell with lipofectamine.  
This figure shows the transfection procedure with lipofectamine. The positively charged 
liposome binds to siRNA and formed lipolexes which perfused in to cells membrane and 
inhibits mRNA of specific gene expression (www.genaxxon.de)  
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The transfection reagents, transfected cell lines and many other parameters can 
affect the efficiency of the transfection. Therefore, the efficiency of transfection was 
measured by flow cytometry. Transfection efficiency was controlled by seeding 
 8 × 104 cells in 12 well plates. Cell density was 60%-70% confluent at time of 
transfection. Then cells were transfected with lipofectamine 3000 labeled FITC in 
DMEM medium without serum and antibiotics according to the following table: 
Reagent 
Volume 
(12 well plate) 
Lipofectamine 3000 
6 µl 
FITC SiRNA 
9 µl 
DMEM medium 
135 µl 
Final Lipoplex Volume 
150 µl 
 
To see the real transfection efficiency, a mock control is included, which means that 
the same amount of the transfection reagent without fluorescence tag is applied to 
cells. After 24 hrs the viability and morphology of cells were checked and compared 
with the control group (cells without lipofection reagents) by microscopy. Then, cells 
were trypsinized and washed with PBS and prepared for flow cytometry to evaluate 
the GFP intensity in transfected cells. The efficiency of transfection with lipofectamine 
3000 was approximately 80%-90% for each siRNAs in the HCC cell lines (Fig 2.5).  
Table 2.6. Amount of components for lipofection assay. 
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Control 
Mock 
Transfected-FITC 
Transfected-FITC 
Transfected- FITC 
Figure 2.5. The efficiency of transfection was tested with FITC-siRNA by 
flow cytometry. 
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To knock down the expression of TET2 and TET3, HCC cells were seeded in 6 well 
plates at the density of 2 × 105 in 2 ml of DMEM medium. siRNAs were transfected 
with lipofectamine reagent according to the manufacturer’s instruction. The final 
siRNAs concentration was 50 nM. Cells were transfected and then were stimulated 
with 5-AZA. After 48 hrs of incubation with 5-AZA, untreated cells and treated cells 
were harvested for RNA and protein isolation. The scrambled /nonsense siRNA was 
used as a negative control which indicates unintended off-targeting. The siRNA 
sequences are listed in Table 2.7. 
 
 
2.2.10  PathScan Stress and Apoptosis signaling antibody array kit 
(Fluorescent Readout) 
The PathScan stress and apoptosis signaling antibody kit uses glass slide as the 
planer surface and is based upon the sandwich immunoassay principle (Cat Nr: 
7323, Cell Signaling Technology, Inc., MA, USA). The array kit includes 19 signaling 
molecules related to stress response or apoptosis (Table 2.6.), cell lysates were 
prepared by using Cell Lysis Buffer (0.5 ml per 10 cm diameter) according to 
Pathscan protocol (http://media.cellsignal.com/pdf/7323.pdf [29.02.2016]). Lysates 
Table 2.7. The siRNA sequences for transfection. 
Gene Name Target Sequence 5’ or 3’ Mod 
Control Scrambled siRNA 5’AACAGTCGCGTTTGCGACTGG3’ 3’ FLU 
TET2 TET2-siRNA 5’ CAAGACCAATGTCAGAA 3’ 3’ FLU 
TET3 TET3-siRNA 5’ GATGAAGGTCCATATTA 3’ 5’ CY3 
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were diluted to 0.5 mg/ml immediately before starting the assay. The multi-well 
gasket affixed to the glass slide, then 100 µl of blocking buffer was added to each 
well and then were incubated in RT in 15 min. After removing blocking buffer, 75 µl of 
diluted lysate was added to each well and incubated for 2 hrs in room temperature. 
Wells were washed with array washing buffer and then detection antibody cocktail 
was added to each well and incubated for 1 hour on orbital shaker. After washing, 75 
µl 1X DyLight 680-linked Streptavidin was added to each well and incubated for 30 
min and wells were washed for 4 times. Slides were removed from plastic dish and 
images were captured by a digital imaging system capable of exciting at 680 nm and 
detecting at 700 nm (INTAS Science Imaging GmbH, Göttingen, Germany). Spot 
intensity was quantified with Image J 1.45s software (NIH, USA). Tubulin considered 
as an endogenous reference.  List of genes involved in the array are listed in Table 
2.8. 
Target Site 
Positive Control  
 Negative Control  
P44/42MAPK (ERK1/2) Thr202/ Tyr204 
AKT Ser437 
Bad Ser136 
Table 2.8. List of Stress and Apoptosis genes involved in the array. 
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HSP27 Ser82 
Smad2 Ser456/467 
P53 Ser15 
P38 MAPK Thr180/Tyr182 
SAPK/JNK Thr183/Tyr185 
PARP ASP214 
Caspase-3 ASP175 
Caspase-7 ASP198 
IkB Total 
CHK1 Ser345 
CHK2 Thr68 
IkBa Ser32/36 
eIF2 Ser51 
TAK Ser412 
Survivin Total 
Tubulin Total 
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2.2.11 Chromatin modification array 
The Human Epigenetic Chromatin Modification Enzymes RT² Profiler™ PCR Array 
(Cat. No: 33231 PAHS-085ZA, QIAGEN, MD, USA) profiles the expression of 84 key 
genes encoding enzymes which affect genomic DNA and histones status to regulate 
chromatin accessibility and therefore gene expression.  Genes which provided by the 
array exhibit different expression profiles in tumor cells relative to normal cells, 
suggesting a role for chromatin modification and remodeling in oncogenesis. 
Following genes are included in the array: 
 
To distinguish the variation of chromatin modification among HCC cell lines and PHH, 
chromatin modification array was used. Four common HCC cell lines including; Huh7, 
HepG2, HLE, AKN1 and primary human hepatocytes (PHH) were investigated. RNA 
DNA Methyltransferases: DNMT1, DNMT3A, DNMT3B. 
 
Histone Acetyltransferase: ATF2, CDYL, CIITA, CSRP2BP, ESCO1, ESCO2, 
HAT1, KAT2A (GCN5L2), KAT2B (PCAF), KAT5 (HTATIP), KAT8, KAT7, KAT6A, 
KAT6B, NCOA1, NCOA3, NCOA6. 
 
Histone Methyltransferases: CARM1 (PRMT4), DOT1L, EHMT2, MLL, MLL3, 
PRMT1, PRMT2, PRMT3, PRMT5, PRMT6, PRMT7, PRMT8, SETDB2, SMYD3, 
SUV39H1. 
 
SET Domain Proteins (Histone Methyltransferases Activity): ASH1L, MLL3, 
MLL5, NSD1, SETD1A, SETD1B, SETD2, SETD3, SETD4, SETD5, SETD6, SETD7, 
SETD8, SETDB1, SUV39H1, SUV420H1, WHSC1. 
 
Histone Phosphorylation: AURKA, AURKB, AURKC, NEK6, PAK1, RPS6KA3, 
RPS6KA5. 
 
Histone Ubiquitination: DZIP3, MYSM1, RNF2, RNF20, UBE2A, UBE2B, USP16, 
USP21, USP22. 
 
DNA / Histone Demethylases: KDM1A, KDM5B, KDM5C, KDM4A, KDM4C, KDM6B, 
MBD2. 
 
Histone Deacetylases: HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, 
HDAC7, HDAC8, HDAC9, HDAC10, HDAC11. 
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of 5 different donors of PHH and 5 different passage numbers of HCC cell lines were 
isolated. The quality of the RNA was checked and quantified. The equal amounts of 5 
µg of each cell types RNA were mixed together. The pooled RNA was purified with 
Rneasy Lipid Tissue Mini Kit according to manufacturer’s instruction (QIAGEN, MD, 
USA). 
 
 
After purification step the RNA amount was quantified and the integrity of RNA was 
checked. RT2 First strand synthesis kit was used in order to eliminate Genomic DNA 
contamination and reverse transcription which was performed according to 
manufacturer’s protocol (QIAGEN, MD, USA). Then the expression of GAPDH was 
tested in all samples. Then RT2 SYBR Green mastermixes (QIAGEN, MD, USA) was 
used for performing real-time PCR for RT2 PCR array according to manufacturer’s 
protocol.  
Real-time PCRs were performed as follows: denaturation for 10 min at 95°C, 
amplification with 40 cycles and 15 seconds at 95°C, 1 min at 60°C and 15 seconds 
at 72°C (Step One PlusTM Real -Time PCR System, Life technologies, CA, USA). 
Add 70 % 
Ethanol to 
aqueous 
phase 
Bind total 
RNA 
Wash 
 RNA Elute Add 1ml 
Qiazol 
Add 
Chloroform
Separate 
phases  
Figure 2.6. Schematic of RNA purification. 
This figure shows the RNA purification steps by using Rneasy Lipid Tissue Mini Kit 
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The RT2 profiler PCR array genes abbreviations and details are included in Table 
2.9. 
    Table 2.9 . Gene information included in RT² Profiler PCR array. 
N Uni-gene Refseq Symbol Description 
A01 Hs.491060 NM_018489 ASH1L 
Ash1 (absent, small, or 
homeotic)-like (Drosophila) 
A02 Hs.592510 NM_001880 ATF2 Activating transcription factor 2 
A03 Hs.250822 NM_003600 AURKA Aurora kinase A 
A04 Hs.442658 NM_004217 AURKB Aurora kinase B 
A05 Hs.98338 NM_003160 AURKC Aurora kinase C 
A06 Hs.720136 NM_199141 CARM1 
Coactivator-associated arginine 
methyltransferase 1 
A07 Hs.269092 NM_004824 CDYL Chromodomain protein, Y-like 
A08 Hs.701991 NM_000246 CIITA 
Class II, major histocompatibility 
complex, transactivator 
A09 Hs.488051 NM_020536 CSRP2BP CSRP2 binding protein 
A10 Hs.202672 NM_001379 DNMT1 
DNA (cytosine-5-)-
methyltransferase 1 
A11 Hs.515840 NM_022552 DNMT3A 
DNA (cytosine-5-)-
methyltransferase 3 alpha 
A12 Hs.713611 NM_006892 DNMT3B 
DNA (cytosine-5-)-
methyltransferase 3 beta 
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B01 Hs.713641 NM_032482 DOT1L 
DOT1-like, histone H3 
methyltransferase (S. 
cerevisiae) 
B02 Hs.409210 NM_014648 DZIP3 
DAZ interacting protein 3, zinc 
finger 
B03 Hs.709218 NM_006709 EHMT2 
Euchromatic histone-lysine N-
methyltransferase 2 
B04 Hs.464733 NM_052911 ESCO1 
Establishment of cohesion 1 
homolog 1 (S. cerevisiae) 
B05 Hs.99480 NM_001017420 ESCO2 
Establishment of cohesion 1 
homolog 2 (S. cerevisiae) 
B06 Hs.632532 NM_003642 HAT1 Histone acetyltransferase 1 
B07 Hs.88556 NM_004964 HDAC1 Histone deacetylase 1 
B08 Hs.26593 NM_032019 HDAC10 Histone deacetylase 10 
B09 Hs.744132 NM_024827 HDAC11 Histone deacetylase 11 
B10 Hs.3352 NM_001527 HDAC2 Histone deacetylase 2 
B11 Hs.519632 NM_003883 HDAC3 Histone deacetylase 3 
B12 Hs.20516 NM_006037 HDAC4 Histone deacetylase 4 
C01 Hs.438782 NM_005474 HDAC5 Histone deacetylase 5 
C02 Hs.6764 NM_006044 HDAC6 Histone deacetylase 6 
C03 Hs.200063 NM_001098416 HDAC7 Histone deacetylase 7 
C04 Hs.310536 NM_018486 HDAC8 Histone deacetylase 8 
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C05 Hs.196054 NM_178425 HDAC9 Histone deacetylase 9 
C06 Hs.463045 NM_021078 KAT2A K(lysine) acetyltransferase 2A 
C07 Hs.533055 NM_003884 KAT2B K(lysine) acetyltransferase 2B 
C08 Hs.397010 NM_006388 KAT5 K(lysine) acetyltransferase 5 
C09 Hs.491577 NM_006766 KAT6A K(lysine) acetyltransferase 6A 
C10 Hs.599543 NM_012330 KAT6B K(lysine) acetyltransferase 6B 
C11 Hs.21907 NM_007067 KAT7 K(lysine) acetyltransferase 7 
C12 Hs.533803 NM_032188 KAT8 K(lysine) acetyltransferase 8 
D01 Hs.591518 NM_015013 KDM1A 
Lysine (K)-specific demethylase 
1A 
D02 Hs.155983 NM_014663 KDM4A 
Lysine (K)-specific demethylase 
4A 
D03 Hs.709425 NM_015061 KDM4C 
Lysine (K)-specific demethylase 
4C 
D04 Hs.443650 NM_006618 KDM5B 
Lysine (K)-specific demethylase 
5B 
D05 Hs.631768 NM_004187 KDM5C 
Lysine (K)-specific demethylase 
5C 
D06 Hs.223678 NM_001080424 KDM6B 
Lysine (K)-specific demethylase 
6B 
D07 Hs.25674 NM_003927 MBD2 
Methyl-CpG binding domain 
protein 2 
D08 Hs.258855 NM_005933 KMT2A 
Myeloid/lymphoid or mixed-
lineage leukemia (trithorax 
homolog, Drosophila) 
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D09 Hs.647120 NM_170606 KMT2C 
Myeloid/lymphoid or mixed-
lineage leukemia 3 
D10 Hs.592262 NM_182931 KMT2E 
Myeloid/lymphoid or mixed-
lineage leukemia 5 (trithorax 
homolog, Drosophila) 
D11 Hs.744921 NM_001085487 MYSM1 
Myb-like, SWIRM and MPN 
domains 1 
D12 Hs.596314 NM_003743 NCOA1 Nuclear receptor coactivator 1 
E01 Hs.592142 NM_181659 NCOA3 Nuclear receptor coactivator 3 
E02 Hs.736403 NM_014071 NCOA6 Nuclear receptor coactivator 6 
E03 Hs.197071 NM_014397 NEK6 
NIMA (never in mitosis gene a)-
related kinase 6 
E04 Hs.106861 NM_022455 NSD1 
Nuclear receptor binding SET 
domain protein 1 
E05 Hs.435714 NM_002576 PAK1 
P21 protein (Cdc42/Rac)-
activated kinase 1 
E06 Hs.20521 NM_001536 PRMT1 
Protein arginine 
methyltransferase 1 
E07 Hs.661229 NM_001535 PRMT2 
Protein arginine 
methyltransferase 2 
E08 Hs.152337 NM_005788 PRMT3 
Protein arginine 
methyltransferase 3 
E09 Hs.367854 NM_006109 PRMT5 
Protein arginine 
methyltransferase 5 
E10 Hs.26006 NM_018137 PRMT6 
Protein arginine 
methyltransferase 6 
E11 Hs.679580 NM_019023 PRMT7 
Protein arginine 
methyltransferase 7 
E12 Hs.504530 NM_019854 PRMT8 
Protein arginine 
methyltransferase 8 
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F01 Hs.591490 NM_007212 RNF2 Ring finger protein 2 
F02 Hs.729085 NM_019592 RNF20 Ring finger protein 20 
F03 Hs.445387 NM_004586 RPS6KA3 
Ribosomal protein S6 kinase, 
90kDa, polypeptide 3 
F04 Hs.510225 NM_004755 RPS6KA5 
Ribosomal protein S6 kinase, 
90kDa, polypeptide 5 
F05 Hs.297483 NM_014712 SETD1A SET domain containing 1A 
F06 Hs.507122 NM_015048 SETD1B SET domain containing 1B 
F07 Hs.517941 NM_014159 SETD2 SET domain containing 2 
F08 Hs.510407 NM_199123 SETD3 SET domain containing 3 
F09 Hs.606200 NM_017438 SETD4 SET domain containing 4 
F10 Hs.288164 NM_001080517 SETD5 SET domain containing 5 
F11 Hs.731691 NM_024860 SETD6 SET domain containing 6 
F12 Hs.480792 NM_030648 SETD7 
SET domain containing (lysine 
methyltransferase) 7 
G01 Hs.443735 NM_020382 SETD8 
SET domain containing (lysine 
methyltransferase) 8 
G02 Hs.643565 NM_012432 SETDB1 SET domain, bifurcated 1 
G03 Hs.631789 NM_031915 SETDB2 SET domain, bifurcated 2 
G04 Hs.567571 NM_022743 SMYD3 
SET and MYND domain 
containing 3 
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G05 Hs.522639 NM_003173 SUV39H1 
Suppressor of variegation 3-9 
homolog 1 (Drosophila) 
G06 Hs.632120 NM_016028 SUV420H1 
Suppressor of variegation 4-20 
homolog 1 (Drosophila) 
G07 Hs.379466 NM_003336 UBE2A 
Ubiquitin-conjugating enzyme 
E2A 
G08 Hs.612096 NM_003337 UBE2B 
Ubiquitin-conjugating enzyme 
E2B 
G09 Hs.99819 NM_006447 USP16 Ubiquitin specific peptidase 16 
G10 Hs.8015 NM_012475 USP21 Ubiquitin specific peptidase 21 
G11 Hs.462492 NM_015276 USP22 Ubiquitin specific peptidase 22 
G12 Hs.113876 NM_007331 WHSC1 
Wolf-Hirschhorn syndrome 
candidate 1 
H01 Hs.520640 NM_001101 ACTB Actin, beta 
H02 Hs.534255 NM_004048 B2M Beta-2-microglobulin 
H03 Hs.544577 NM_002046 GAPDH 
Glyceraldehyde-3-phosphate 
dehydrogenase 
H04 Hs.412707 NM_000194 HPRT1 
Hypoxanthine 
phosphoribosyltransferase 1 
H05 Hs.546285 NM_001002 RPLP0 Ribosomal protein, large, P0 
H06 N/A SA_00105 HGDC 
Human Genomic DNA 
Contamination 
H07 N/A SA_00104 RTC Reverse Transcription Control 
H08 N/A SA_00104 RTC Reverse Transcription Control 
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H09 N/A SA_00104 RTC Reverse Transcription Control 
H10 N/A SA_00103 PPC Positive PCR Control 
H11 N/A SA_00103 PPC Positive PCR Control 
H12 N/A SA_00103 PPC Positive PCR Control 
 
2.2.12 Biotransformation in liver (Enzymatic activity of Cytochrome P450 
in Liver) 
2.2.12.1 Phase I (CYPs) and phase II enzymatic activity 
The enzymatic activity was analyzed with a modified fluorescence-based method 
[Donato et al., 2004; Ehnert et al., 2008]. Cells were incubated for 120 min (kinetic 
measurement within 5 min interval) with different substrates diluted in plain medium 
(Tables 2.10 and 2.11). The cells converted substrates to metabolites and these 
change in fluorescence intensity during this process was measured with a plate 
reader. Moreover, in the phase I substrates, 1.5 mM (15 μl/ml DMSO) salicylamide 
buffer, 2 mM (10 μl/ml DMSO) probenecid buffer and 0.01 mM (1 μl/ml DMSO) buffer 
dicoumarol buffer (10 mM in DMSO) were added to prevent spontaneous 
fluorescence decay. Wells without cells with reaction solution (Medium without FCS 
with substances) is used as a background control. Methanol fixed cells were used as 
negative control. The amount of product formed was normalized to total cell number. 
Total cell number was determined by SRB staining of fixed cells. The measured 
values were quantified by using their respective standard curves and the standard 
curves were consistent through all experiments.  
The measured values were quantified by using their respective standard curves. 
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Results were expressed as picomoles of metabolite formed per minute and per 106 of 
total cell number. Enzyme activity measurements were analyzed with the help of the 
GraphPad Prism software. 
   Table 2.10. Substrates used during the study of phase I. 
Reaction Substrate 
Substrate conc.  
(µM / 100µl) 
Metabolite Excitation/Emission  
CYP1A1/2 7-EC 25  HC 355 nm/460 nm 
CYP3A4 BFC 5  HFC 355 nm/520 nm 
CYP2E1 MFC 2  HFC 355 nm/520 nm 
CYP2C9 DBF 5 HFC 355 nm/520 nm 
 
 
 
 
Reaction Substrate 
Substrate conc. 
(μM / 100 µL) 
Excitation / Emission 
UGT activity 4-MU 6,25  355 nm/460 nm 
 
Table 2.11. Substrates used during the study of phase II. 
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Enzyme Standard 
Concentration 
(In 100µL) 
Y (Fluorescence 
Intensity) = 
X (M) = R2 
CYP1A1 HC 2 µM 
120.89 x +80.258 (Y- 80.258) / 
120.89 
0.9998 
CYP3A4 HFC 25 µM 
137.23x + 79.393 (Y- 79.393) / 
137.23 
0.9988 
CYP2C9 FL 1,25 µM 
1704.7x + 51.098 (Y- 51.098) / 
1794.7 
0.9999 
UGT2B7 4-Mu 6,25 µM 
95.558x + 78.982 (Y– 78.982) / 
95.558 
0.9999 
 
2.2.12.2 Sulforhodamine B (SRB) staining 
For SRB staining [Skehan et al., 1990] cells were fixed to culture plastic with ice cold 
fixation buffer (95% Ethanol, 100 μl/well). The cells were incubated for at least 1 hour 
at –20C. Then fixation buffer was removed and cells were washed with H2O. Fixed 
cells were stained for 30 min (dark, RT) with 0.4% SRB dissolved in 1% acetic acid 
(100 μl/well). At the end of the staining period SRB solution was removed and cells 
were washed three times with 1% acetic acid in order to washout unbound dye. After 
being rinsed, plates were air dried until no standing moisture was visible. Bound SRB 
was solubilized with 10 mM un-buffered TRIS (pH =10.5, 100 μl/well) for 10-15 min 
on a shaker (RT, dark). The OD at 565 nm (SRB) and 690 nm (impurities) were 
measured with OMEGA plate reader (BMG Labtech GmbH, Offenburg, Germany). 
Table 2.12. Standard curves for phase I and phase II enzyme activity measurement. 
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The SRB OD of the different number of seeded cells was determined with OMEGA 
plate reader. For calculation OD690 nm (background and impurities) is subtracted from 
OD565 nm (SRB concentration) and the standard curve was determined for each cell 
line (Table 2.11). 
 
SRB 
Standard 
Curve 
Y (Fluorescence 
Intensity) = 
X (M) = R2 
PHH 6E-05x - 0.3433 (Y + 0,3433) / 0.00006 0.00006 
HLE 7E-05x - 0.1293 (Y + 0,1293) / 0.00007 0,00007 
Huh7 8E-05x – 0.048 (Y + 0.048) / 0.00008 0.00008 
HepG2 3E-05x + 0.0028 (Y - 0.0028) / 0.00003 0.00003 
AKN1 4E-05x + 0.0055 (Y - 0.0055) / 0.00004 0.00004 
2.2.13 Ammonia detoxification 
The urea production by the cells was measured by the photometric quantification of 
urea, a decomposition product of ammonia in PHH. PHH were washed three times 
with DPBS. Then, the cells were incubated with 100 μl (96-well plate) of 300 mM 
NH4Cl in reaction buffer (1 mM MgCl2 and 1 mM sodium pyruvate in DPBS) for 24 
hrs at 37ºC, 5% CO2. Wells without cells were used as background subtraction from 
well with cells. After 24 hrs, 80 μl of culture supernatant were transferred to a new 
96-well plate for urea quantification. Simultaneously, a urea standard curve was 
prepared in the same 96-well plate. Then, 60 μl of O-Phthalaldehyde solution (1.5 
Table 2.13. SRB Stand Curve for HCC cell lines. 
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mM O-Phthalaldehyde, 4 mM Brij-35, 0.75 M H2SO4) and 60 μl of NED’s reagent (2.3 
mM N-(1-naphthyl) ethylenediaminedihydrochloride, 0.08 M boric acid, 4 mM Brij-35, 
2.25 M H2SO4) were added in each well and incubated for 2 hrs at 37 ºC, 5% CO2. 
After the incubation time, the absorption was measured at a wavelength of λ = 460 
nm with a plate reader [Jung et al., 1975; Zawada et al., 2009].
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3  Results 
3.1 Alteration of DNA methylation landscape in HCCs  
Numerous studies have reported that tumor cells exhibit a major disruption in the 
regulation of the DNA methylation pattern in cancers including HCCs [Bird, 1995; 
Santini et al., 2001; Watanabe & Maekawa, 2010; Yang et al., 2001; Yu et al., 2002]. 
It has been shown that several critical genes, which seem to be important in 
tumorigenesis, are hypermethylated in HCCs and most importantly in CpG Island of 
the promotor [Yu et al., 2002]. It has been reported that in various type of cancers 
5hmC level drastically decreased and the level was dependent on tumor stages. 
Therefore, we investigated the level of 5mC and 5mC in HCCs. 
3.1.1 5hmC is decreased in human HCC tissues  
It was shown that the loss of 5hmC has a significant role in development of different 
types of cancer including brain, melanoma, colon and liver [Haffner et al., 2011; 
Huang et al., 2013; Ivanov et al., 2013; Ko et al., 2010]. The genomic distribution of 
5hmC and 5mC in HCC tissue-microarray-paraffin-embedded tissues was evaluated 
by immunohistochemistry (IHC) staining. By evaluating 55 HCC tissue samples, a 
significant (p < 0.001) decline of 5hmC (quantified via IHC, Fig.3.1) along with a 
significant (p < 0.001) increase of 5mC as compared to noncancerous liver tissue of 
the same patient, was observed in HCC liver samples (Fig.3.1 A). The 
heterogeneous loss or reduction of 5hmC was observed in most of the HCC tissue 
samples and 5mC was highly generated in HCC samples as compared with 
corresponding normal liver. Hematoxylin was used as a nuclear counterstain. To 
assess the potential diagnostic value of 5hmC and 5mC, a ROC curve analysis was 
performed. The associated area under the curve (AUC) was used to confirm the 
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diagnostic value of 5hmC and 5mC. The AUC of 5hmC was 0.79 95% confidence 
interval [CI] 0.6915 to 0.8814, p< 0.0001) and the AUC of 5mC was 0.95 (95% 
confidence interval [CI] 0.9057-0.9892, p < 0.0001) (Fig. 3.1 C). As the ROC curves 
for HCC tissue samples show, the detection of the depletion of 5hmC and the 
increase of 5mC in HCC tissue provide a reliable prognosis marker for HCC therapy. 
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3.1.2 5hmC is decreased in human HCC tissues and cell lines  
To assess the differential distribution of 5hmC more particularly and quantitate in 
HCC cell lines as compared with primary human hepatocytes (PHH), the 
immunofluorescence microscopy coupled with quantitative image analysis was used. 
We observed a significant difference in 5hmC staining intensities between HCC cell 
lines and PHH. The immunofluorescence staining for 5hmC normalized to Hoechst. 
The quantification of 5hmC staining intensity showed the reduction of 5hmC in HCC 
cell lines (Huh-7, HLE and HLF) as compared to primary human hepatocytes (Fig 
3.2. A).These results confirmed the loss of 5hmC in HCCs. 
Figure 3.1. Distribution of 5-hydroxymethylcytosine (5hmC) and 5-methylcytosine 
(5mC) in HCC tissues.  
A) IHC was performed using antibodies against 5hmC and 5mC in human normal and 
HCC tissues, the mean values of the IHC are shown (each group N=55, n=3). Six pictures 
are presented for each condition. B) The reduction of the 5hmC generation and the 
increase of 5mC were observed in HCC samples compared with corresponding normal 
liver samples. Data are represented as Box Plot (Whisker, Tukey). C) ROC curve for 5mC 
and 5hmC of 55 of HCC samples showed the accuracy of the 5mC-5hmC detection. 
Statistical methods included Paired t-test and independent samples t-test. All statistical 
tests were considered significant at α = 0.05 (p < 0.05). 
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3.1.3  Reduction of 5hmC correlates with decreased TET2 and TET3 gene 
expression in HCC tissues and cell lines 
To understand, the important cellular factors responsible for 5hmC reduction in 
HCCs; we determined the expression of IDH1, IDH2, TET1, TET2 and TET3 by qRT-
PCR. Despite reports by others that TET1 is down-regulated in HCC tissue compared 
with ‘normal’ liver tissue [Liu et al., 2013; Yang et al., 2013], we found no TET1 
expression by qRT-PCR in normal adult human liver tissue, HCC tissue as well as 
HCC cell lines or human hepatocytes (data not shown). 
 The expression of TET1 in our samples was at the detection limit with the very small 
difference of Ct values. In contrast, we found that the expression of TET2 and TET3 
as well as the upstream genes IDH1 and IDH2 were significantly decreased in 
human HCC tissues as compared to matched ‘normal’ liver tissues (Fig.3.3 A). These 
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Figure 3.2. Distribution of 5-hydroxymethylcytosine (5hmC) in HCC cell lines. 
A) IF staining was performed by using the antibody against 5hmC (Red) for HCC paraffin 
embedded tissues, HCC cell lines (Huh7, HLE and HLF) and hHep. Cell nuclei were 
counterstained with Hoechst 33342 (blue) (white arrowhead; scale bar, 200 µm). B) The 
quantification of 5hmC staining intensity showed the reduction of 5hmC in HCC cell lines (Huh-
7, HLE and HLF) as compared to primary human hepatocytes). Cell nuclei were 
counterstained with Hoechst 33342 (blue) (white arrowhead; scale bar, 200 µm). For 
quantification, 5hmC positive nuclei were counted. Statistical methods included Paired t-test 
and independent samples t-test. All statistical tests were considered significant at α = 0.05 (p < 
0.05) 
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data were confirmed in HCC cell lines (Huh7, HLE and HLF) in comparison with 
freshly isolated PHH (Fig.3.3 B). Our data show that a decrease in the expression of 
IDHs and of TETs, suggested that these proteins could play a specific a role in the 
observed reduction of 5hmC in HCCs (Fig.3.3 C). After screening different 
housekeeping genes, we have chosen Beta-2-Microglobulin (B2M) whose expression 
was stable without much variation among the tested HCC and normal liver tissue 
samples for the normalization of our RT-qPCR results. 
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3.2 Effect of 5-Azacytidine on HCC cells proliferation and viability  
Incubation of the three tested HCC cell lines with 5-AZA showed a dose- and time-
dependent reduction of mitochondrial activity, as measured by Resazurin conversion 
(Fig.3.4 A). HCC cell lines were treated with 5-20 µM 5-AZA for 24, 48, 72 and 96 hrs 
(fresh drug added every 24 hrs). Resazurin assay indicate that HCC cells survival 
reduced by doses of 5 µM and the viability was significantly reduced by 5-AZA at all 
tested concentrations. However, 20 µM of 5-AZA reduced the cell viability 
dramatically after 48 hrs. A time dependent inhibition of cell viability was observed 
upon treatment with 5-AZA and as the growth inhibition effect of 5-AZA requires time 
to be incorporated into genomic DNA and change the DNA methylation status. To 
strengthen this result, the effect of 5-AZA on cell proliferation was additionally tested 
by analyzing the proliferation cell nuclear antigen (PCNA) antigen with 
Immunofluorescence staining [Waseem & Lane, 1990]. The IF staining indicated a 
significant decrease of PCNA nuclear staining of treated cells compared to untreated 
cells after 48 hrs (Fig.3.4 B). Decrease of PCNA protein expression showed the 
inhibition effect of 5-AZA on HCC cell proliferation. 
Figure 3.3. Reduction of 5hmC is associated with the substantial reduction of IDH1 & 2 
and TET2 & 3 gene expression. 
A) The expression of TET2, TET3, IDH1 and IDH2 decreased in HCC tissues in comparison 
to the matched normal liver. Real-time qRT-PCR was used to determine TETs and IDHs 
relative mRNA levels in HCCs while using β2M as an internal control for normalization. Data 
are expressed as fold change in mRNA expression compared to the normal liver control 
(indicated by dashed line at 1 (The Data are presented as Box Plot (N=9, n=3): Center line 
represents the median, box limits represent the first and third quartiles, and whiskers 
represent 1.5 times the interquartile range (The p value were assessed by Student’s t test, 
bars, mean ± S.E; p*** < 0.0001 for TET2, TET3, IDH1 and IDH2). B) The same pattern was 
confirmed by comparing HCC cell lines (Huh7, HLE; HLF) to primary human hepatocytes 
(N=4, n=3). (P value assessed by one way ANOVA, bars, mean ± S.E) (p < 0.001). C) 
Shows schematic diagram of the aberrant epigenetic status due to the reduction of TETs and 
IDHs activity which may lead to the depletion of the 5hmC generation in HCCs. 
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To determine whether 5-AZA induces apoptosis, hypodiploid DNA was measured by 
flow cytometric measurement. Further analyses revealed that 5-AZA induced 
apoptosis to a certain extent in all tested HCC cell lines (Fig.3.4 D) which is 
paralleled by an increased LDH enzyme release from HCCs after treatment with 5-
AZA (Fig.3.4 C).  
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3.3 5-Azacytidin triggers active demethylation in HCC cells 
It is known that 5-AZA induces passive demethylation through inhibition of DNMT 
[Jones et al., 1983], however it is not known to our knowledge if it has an influence 
on active demethylation through induction of TET expression. Treatment of HCC cell 
lines (Huh-, HLE and HLF) with 5-AZA for 24 and 48 hrs led to a significant increase 
in 5hmC positive cells compared to untreated HCC cells (Fig.4 A). To further 
investigate a potential active demethylation process through conversion of 5mC to 
5hmC, the expression of TET2 and TET3 was determined. 5-AZA-stimulated cells 
displayed a significantly increased expression of TET2 and TET3, while the 
expression of IDHs is not influenced (Fig.3.5 A, C). Increased expression of TET2 
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Figure 3.4. Distinct effect of 5-AZA on HCC cell lines viability, proliferation and 
apoptosis. 
 A) the mitochondria activity of cells decreased upon treatment with 5, 10, and 20 µM of 5-AZA 
for 24, 48, 96 and 120 hrs in time and doses dependent manner (N=4, n=3). B) 20 µM of 5-AZA 
inhibited the PCNA expression in HCC cell lines after 48 hrs of incubation (white arrowhead; 
scale bar, 400 µm). C) 20 µM of 5-AZA caused LDH released in HLE and HLF cells after 48 
hrs, however LDH released in culture supernants in Huh7 cells did not increase upon treatment 
of 5-AZA (N=4, n=3). D) 5-AZA induced cell death in HLE and HLF cells. Determination of 
sub2N fractions as marker for apoptosis was measured after treatment of HCC cells with 20 µM 
5-AZA for 48 hrs (P value assessed by Student’s t test, bars show the mean ± S.E of four 
independent experiments). 
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and TET3 upon 5-AZA treatment was confirmed by Western blot analysis (Fig.5 B). 
We next needed to functionally prove if 5-AZA treatment in line with our previous 
work, could trigger oxidation of 5mC to 5hmC through the induction of TET2 and/or 
TET3 expression [Yan et al., 2014] in HCC. If this would be the case, we would have 
strong evidence of an active demethylation process caused by 5-AZA. We were able 
to demonstrate the conversion of 5mC to 5hmC upon 5-AZA treatment depends on 
TET proteins by simultaneous knock down of TET2 and TET3 expression in Huh-7, 
HLE, and HLF cells, using siRNA. mRNA levels of the TET genes could be 
downregulated to approximately 30% for TET2 and 40% for TET3, as compared to 
corresponding transfected cells with control siRNAs (Fig.6 A). In control cells, TET2 
and TET3 mRNA knock down decreased intrinsic 5hmC levels. Upon TET2 knock 
down, 5-AZA (20 μM) treatment was unable to enhance the generation of 5hmC. In 
contrast, 5-AZA still enhanced – although to a much lesser extent – the expression of 
5hmC in TET3 knocked-down HCC cells (Fig.6 B). Overall, these results suggest that 
the enhancing effect of 5-AZA on 5hmC generation in HCC is mainly mediated by 
TET2.  
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Figure 3.5. 5-AZA enhanced the generation of 5hmC in HCC cell lines. 
A) Immunostaining showed that 20 µM of 5-AZA enhances the generation of 5hmC in HCC cell 
lines after 48 hrs (white arrowhead; scale bar, 200 µm). B) The semi-quantitative analysis of 
immunofluorescence staining indicated that the incubation of HCC cells with 5-AZA for 48 hrs 
increased 5hmC level. P are value assessed by Student’s t test, data are represented as mean ± 
SE. 
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Figure 3.6. 5-AZA enhanced the generation of 5hmC through induction of TETs 
expression in HCC cell lines. 
A) 20 µM of 5-AZA induced the expression of TET2 and TET3 in HCC cells after 48 hrs of 
incubation. The mRNA level of TET2 and TET3 genes were determined by quantitative 
real time PCR after 24 hrs and 48 hrs. P values were assessed by one way ANOVA, data 
represented as mean ± SE. B) Expression of TET2 and TET3 was examined by Western 
blot analysis in HCC cell lines (Huh7, HLE and HLF) after treatment with 20 µM 5-AZA for 
24 and 48 hrs. C) 20 µM of 5-AZA didn’t influence the expression of IDH1 and IDH2 in 
HCC cells significantly after 48 hrs of incubation. Real-time qRT-PCR was used to 
determine TETs and IDHs relative mRNA levels in HCC cell lines while using GAPDH as 
an internal control for normalization. 
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Figure 3.7. The effect of 5-AZA is mediated by TET methylcytosine dioxygenase.  
A) siRNAs targeting TET 2 and TET3 decreased the level of TET mRNA to approximately 
30% for TET2 and 40% as compared with corresponding cells transfected cells with 
control siRNAs shown by quantitative RT-PCR. Data were repeated three times and the 
value in columns represents mean ± SD. P values were assessed by Student’s t test;* p < 
0.05 , **p < 0.001 and *** p < 0.001 . B and C) immunostaining shows that knocking down 
the expression of TET genes in HCC cell lines, specifically TET2, decreased the basal 
level of 5hmC signal and attenuated the induction of 5hmC by 5-AZA (20 µM) treatment 
for 48 hrs (white arrowhead; scale bar, 200 µm). 
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3.4 Effect of 5-Azacytidin in combination with Vitamin C on HCC cell 
proliferation 
In recent years, accumulating data provided evidence that in pharmacological doses, 
ascorbic acid (Vitamin C) has cytotoxic effects on cancer cells in vitro and in vivo in 
low micromolar-range This cytotoxicity is caused through pro-oxidative mechanism(s) 
which ascorbyl radicals and H2O2 catalyzed via serum components [Sinnberg et al., 
2014; Venturelli et al., 2014]. We investigated the effect of the Vitamin C as a single 
or combined treatment with 5-Aza (in dose-dependent manner) on HCC cells 
proliferation and cells damage in order to choose an optimum dose of Vitamin C and 
5-AZA for epigenetic study. 
The viability of the cells was monitored after treatment with different concentration of 
5-AZA and L-ascorbic acid 2-phosphate (Vitamin C) for 48 hrs. The viability of treated 
HCC cells was assessed as a function of mitochondrial activity by Resazurin 
conversion assay and compared with the non-treated control cells. A reduced 
mitochondrial activity, reflecting decrease in cell viability was observed in HLE and 
Huh7 cells treated with 5-AZA in both cell lines with and without Vitamin C, whereas 
Vitamin C alone did not compromise the mitochondrial function after 48 hrs (Fig.3.8 
A). In Huh7, cell viability was further reduced when 5-AZA was co-incubated with 
Vitamin C (approximately 30%) (Fig.3.8 A). In both, HLE and Huh7, inhibition of 
proliferation was paralleled by increased intracellular LDH enzyme release, indicating 
membrane leakage after 48 hrs of treatment (Fig.3.8 B). While a very low release of 
LDH was observed with 5-AZA and Vitamin C individually, the combination of 5-AZA 
and Vitamin C showed a high rate of cytotoxicity in both cell lines. 
 Results
   
 
96 
 
Furthermore, flow cytometry analysis of the sub2N population as a measure of cell 
death revealed that the combination of 5-AZA and Vitamin C induced a higher 
number of cells in the Sub 2N in HLE than in solely 5-AZA treated cells (Fig.3.8 C). In 
Huh7 a significant increase in Sub 2N population was observed in cells treated with 
5-AZA + Vitamin C, with a slight increase of LDH compared to 5-AZA single treated 
cells (Fig.3.8 C). 
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Figure 3.8. Vitamin C enhances the cytotoxic effects of 5–AZA and inducing cell 
death in HCC. 
A) 5-AZA alone or together with Vitamin C reduced cell viability in HCC cell lines (HLE 
and Huh7 cells after 48 hrs. B) Combination of 10 µM 5-AZA and 1 mM Vitamin C caused 
more LDH released in HLE and Huh7 compared with the single treatment. C) Flow 
cytometric measurement of sub2N population in HLE and Huh7 showed more cell death in 
combined treated cells than single treated cells. Data were repeated three times and the 
value in columns represents mean ± SD. P values were assessed by one way ANOVA, * 
p < 0.05 , **p < 0.001 and *** p < 0.001 . 
Vit C (1 mM)     -           +            -          + 
5-AZA (10 µM)   -            -            +          + 
Vit C (1 mM)     -           +            -          + 
5-AZA (10 µM)   -            -            +          + 
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3.5 Inhibition of cell proliferation and induction of cell cycle arrest was 
enhanced by the combined treatment of 5-AZA and Vitamin C 
To confirm the anti-proliferative effect of 5-AZA and Vitamin C, expression of 
proliferation cell nuclear antigen (PCNA) was investigated by IF staining .In 
comparison with the untreated control, inhibition of cell proliferation was observed in 
HLE and Huh7 cells treated with Vitamin C (Fig.3.9 A, B). In HLE, 5-AZA treatment 
induced a significantly higher inhibition, which was further enhanced with the 
combination treatment of 5-AZA + Vitamin C. Similarly, in Huh7, a significant 
inhibition of proliferation was observed with both 5-AZA and the combination of 5-
AZA + Vitamin C (Fig.3.9 A, B).  
Next, we determined by flow cytometry the phase of the cell cycle where the 
observed growth inhibition in both cell lines occurred. Cell cycle distribution analysis 
of HLE cells treated with 5-AZA and Vitamin C individually indicated an increase in 
the population of cells in G2 phase. However, a stronger increase in the S phase of 
the cell cycle was noted in cells treated with a combination of 5-AZA + Vitamin C 
(Fig.3.10 A). In Huh7, we observed an increase in the population of cells in the G1 
phase of the cell cycle with 5-AZA and Vitamin C treatment. However, the number of 
cells in the G1 phase was highest with the combination treatment of 5-AZA and 
Vitamin C (Fig.3.10 B).  
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Figure 3.9. 5-AZA and Vitamin C inhibit cell proliferation in HCC. 
A) PCNA nuclear staining of HCC cell lines (HLE and Huh7) illustrated the reduction of 
PCNA positive cells after treatment with Vitamin C and 5-AZA after 48 hrs. PCNA positive 
cells are seen in red, Hoechst is seen in blue (white arrowhead; scale bar, 200 µm). B) 
Graphs represent the calculation of the percentage of PCNA positive cells as an indicator 
of inhibition of cell proliferation in HLE and Huh7. P values were assessed by one way 
ANOVA, * p < 0.05 , **p < 0.001 and *** p < 0.001 . 
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Figure 3.10. 5-AZA and Vitamin C induce cell cycle arrest in HCC. Cell cycle 
analysis indicates the stage of cell cycle arrest in HLE and Huh7. 
A) In HLE cells, the population of cells in G2 phase increased by 5-AZA and Vitamin C 
treatment which in combination the cell cycle was arrested in S phase. B) In Huh7 cells 
the treatment arrest cells in G1 phase. All the data present in graphics are the average of 
experiments (N=3, n=3).  
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3.6 Vitamin C improves the efficacy of 5-AZA in TET-dependent active 
demethylation in HCC cell lines  
In order to further evaluate the changes in the expression of genes which could have 
led to the cell cycle arrest, we first studied if the combination of 5-AZA and Vitamin C 
induces any epigenetic changes in HCC cells. Since 5-AZA and Vitamin C are both 
known to induce active demethylation which reflects changes in the 5hmC status 
[Blaschke et al., 2013; Chen et al., 2013a; Minor et al., 2013; Sajadian et al., 2015], 
we investigated the 5hmC content of the HCC cell lines treated with 5-AZA, Vitamin 
C, and the combination of both after 48 hrs. IF staining of 5hmC indicated the 
presence of a significantly high percentage of 5hmC positive cells with the combined 
treatment as compared to each single treatment in both HLE and Huh7 (Fig 3.11 A). 
Cells treated with Vitamin C alone also showed an increase in 5hmC as compared to 
5-AZA treatment or the untreated control, underlining the importance of Vitamin C in 
active demethylation.  
To investigate whether the effect of this increase in 5hmC intensity after treatment 
was correlated with changes in TET2 and TET3, the mRNA level of TET2 and TET3 
was determined by real time PCR. Cells treated with the combination of 5-AZA and 
Vitamin C demonstrated a significantly increased expression of TET2 and TET3 as 
compared to the individually treated and non-treated controls in both HLE and Huh7 
(Fig 3.11 B). In Huh7 cells, Vitamin C alone enhanced the expression of TET2 and 
TET3 while 10 µM of 5-AZA could not induce a significant increase in expression of 
TET2 and TET3 (Fig.3.11 B).These data confirmed by western blot too (Fig.3.11 C). 
These data indicate the possibility that that Vitamin C when combined together with 
5-AZA could influence the conversion of 5mC to 5hmC by inducing TET2 and TET3 
expression.  
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Figure 3.11. Vitamin C enhances the efficacy of 5-AZA in inducing active 
demethylation and generation of 5hmc by induction of TET expression in HCC. 
A) 5hmC nuclear staining of HCC cell lines (HLE and Huh7) showed an increase of 5hmC 
intensity after treated with 5-AZA + Vitamin C. 5hmC positive cells are seen in red, 
Hoechst is seen in blue (white arrowhead; scale bar, 200 µm). Graphs show the 
calculation of the percentage of 5hmC positive cells as an indicator of active 
demethylation in HLE and Huh7. B) The Quantitative changes in the mRNA expression of 
TET2 and TET3 in HLE and Huh7 cells with the various treatments. Data was normalized 
using GAPDH expression as a reference control. All the data are average of experiments 
(N=3, n=3).  Data were repeated three times and the value in columns represents mean ± 
SD. P values were assessed by one way ANOVA, * p < 0.05 , **p < 0.001 and *** p < 
0.001 .C) Western Blot data confirmed the increase of TET2 and TET3 after treatment 
with 5-AZA and Vitamin C 
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3.7 Induction of active demethylation by 5-AZA and Vitamin C leads to 
downregulation of Snail and activation of GADD45  
Snail is a transcription factor regulated by methylation and has an important role in 
mediating EMT and in inducing tumorigenesis. Therefore, we first evaluated the 
effect of 5-AZA and Vitamin C on Snail expression.  
Our results show that HLE cells treated with Vitamin C or 5-AZA individually, show 
only small changes in the expression of mRNA and protein, while combination of 
both treatments result in a significant reduction (approximately 50 percent) of both 
Snail mRNA and protein levels (Fig.3.12 A and C). In Huh7 cells, a significant 
decrease in the mRNA was noted with Vitamin C and 5-AZA independently, and with 
a combination of 5-AZA + Vitamin C a decrease of 80% of mRNA level of Snail was 
observed in compared with non-treated Huh7 cells. The attenuation of Snail protein 
was also observed after treating Huh7 cells with the combination of 5-AZA and 
Vitamin C for 48hrs (Fig.3.12 A and C). 
We next studied the expression of the DNA damage-inducible gene GADD45 which 
is involved in G1 or G2 cell cycle arrest [Taylor & Stark, 2001] and which has been 
implicated in or has been linked to the progression of HCC [Qiu et al., 2004; Zerbini & 
Libermann, 2005]. We investigated whether the combined treatment of 5-AZA and 
Vitamin C resulted in an altered expression of GADD45. 
In both HLE and Huh7, an increase in GADD45 transcripts and protein was observed 
with Vitamin C and 5-AZA independently, but the increase was significant only with 
the combined treatment of 5-AZA + Vitamin C (Fig.3.12 B and C).  The combination 
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A 
B 
of 5-AZA and Vitamin C induced GADD45 mRNA and protein in both the HCC cell 
lines (Fig.3.12 B and C).Further, to investigate whether the observed changes in the 
expression of Snail and GADD45 are TET-dependent, quantification of Snail and 
GADD45B transcripts was done in TET2 and TET3 KD of HLE and Huh7 treated with 
5AZA + Vitamin C. While Snail expression is down regulated in the SiRNA control, in 
the TET2 and TET3 KDs an increase in the expression of Snail in HLE and Huh7 
was observed with the treatment (Fig.3.12 D). Similar results were observed with 
GADD45B, where an, increase in GADD45B expression was seen in the SiRNA 
controls treated with 5AZA+Vitamin C, however within the TET2 and TET3 KD’s an 
increase in the expression of GADD45B expression was seen with the treatment with 
5-AZA+Vitamin C (Fig.3.12 E). 
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Figure 3.12. Vitamin C enhances the downregulation of Snail and upregulation of GADD45 
expression induced by 5-AZA in HCC. 
A) Real-time PCR quantification illustrated a decrease of Snail mRNA in HLE and Huh7 treated 
with 5 5-AZA + Vitamin C compared to untreated control after 48 hrs. B) 5-AZA together with 
Vitamin C increased the GADD45 mRNA level in HLE and Huh7 after 48 hrs. Data was normalized 
using GAPDH expression as a reference control (N=3, n=3). C) Western blot analysis of HLE and 
Huh7 showed a decrease of Snail protein and an increase of GADD45 proteins in HLE and Huh7 
with combination of both treatments. Data were repeated three times and the value in columns 
represents mean ± SD. P values were assessed by one way ANOVA, * p < 0.05 and *** p < 0.001 . 
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3.8 Upregulated p21 and downregulated Cyclin B1 expression induce cell 
cycle arrest  
In HLE and Huh7 cells, a significant upregulation of P21 mRNA was noted by the 
combination of 5-AZA + Vitamin C as compared to 5-AZA or Vitamin C individual 
treatments (Fig.3.13A and B). In HLE, 5-AZA and 5AZA + Vitamin C treatments 
induced a significant increase in p21 protein, whereas in Huh7 the increase in p21 
protein was higher in the combination treatment of 5-AZA +Vitamin C than with 5-
AZA alone. Since Snail represses p21[Takahashi et al., 2004], it is possible that the 
increase in p21 may be attributed to a corresponding decrease in the Snail protein in 
both HLE and Huh7 leading to the arrest of the cells in G1, S and or G2 phases of 
the cell cycle.  
We also investigated changes in Cyclin B1 protein expression as a downstream 
target of P21, which is essential for the progression of cells from G2 to the M phase 
of the cell cycle (Fig.3.13 B and C). In HLE, we observed that the expression of 
Cyclin B1 decreased with independent Vitamin C treatment but increased with 
independent 5-AZA treatment. However again, only the combination of 5-AZA + 
Vitamin C reduced the expression of Cyclin B1 of 60% in compared to non-treated 
HLE cells. As a consequence of Cyclin B1 decrease, cells in the G2 phase are 
inhibited to progress to the M phase, which means that cell arrest takes place in the 
G2/M phase of the cell cycle. In Huh7 cell line, however, we observed a significant 
decrease (approximately 40%) of Cyclin B1 with 5-AZA treatment alone. 
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Figure 3.13. Increased P21 and reduced cyclin B1 by 5-AZA and Vitamin C in HCC lead to cell 
cycle arrest. 
A) Quantitative analysis of Real-time PCR shows an increase of P21 mRNA level in HLE and Huh7 
cells treated with Vitamin C, 5-AZA and 5-AZA + Vitamin C compared to untreated controls after 48 
hrs. Data was normalized using GAPDH expression as a reference control. Data were repeated three 
times and the value in columns represents mean ± SD. P values were assessed by one way ANOVA, 
* p < 0.05 and ** p < 0.01. B) Western blot analysis showed an increase of P21 in 5-AZA treated cells 
which induced in combined treated cells and a decrease of Cyclin B1 proteins in HLE and Huh7 with 
5-AZA + Vitamin C treatment.  
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3.9 Increased E-cadherin expression indicates a possible shift of cells 
towards epithelial phenotype  
Snail is a direct repressor of E-cadherin and induces EMT in HCC [Qiu et al., 2004; 
Van Zijl et al., 2009]. In addition, it was reported that Vitamin C induces MET by 
induction of TET proteins which may prevent cancer cells from attaining further 
invasive traits [Chen et al., 2013a]. Thus, we were interested whether or not Vitamin 
C and/or 5-AZA influence E-cadherin expression in HCC lines. In both HLE and Huh7 
cell lines treated with Vitamin C, 5-AZA, and 5-AZA + Vitamin C, we observed an 
increase in E-Cadherin mRNA and protein expression as compared to the untreated 
controls (Fig 6 A and B). In both HCC cell lines, the combination of 5-AZA + Vitamin 
C showed a higher expression than 5-AZA alone. Further, it was interesting to note 
that in both cases Vitamin C independently was also able to induce a high expression 
of E-cadherin (3.14 A and B)  
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Figure 3.14. Increased E-cadherin expression in HCC treated with 5-AZA and 
Vitamin C. 
A) Quantitative Real-time analysis showed an increase in E-cadherin mRNA expression in 
HLE and Huh7 cells treated with Vitamin C compared to untreated controls after 48 hrs. 
Data were normalized using GAPDH expression as a reference control (N=3, n=3). Data 
were repeated three times and the value in columns represents mean ± SD. P values 
were assessed by one way ANOVA, * p < 0.05 and ** p < 0.01. B) Western blot analysis 
of E-cadherin proteins in HLE and Huh7 cells with various treatments after 48 hrs. 
GAPDH was used as a loading control. 
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3.10 Effect of 5-AZA and Vitamin C on level of NF-κB and P16 protein 
expression in HLE and Huh7 cell lines 
The combination of 5-AZA and Vitamin C attenuated the NF-κB protein with a 
concomitant increase of P16 protein level in Huh7 cells after 48 hrs. In HLE cells, 5-
AZA and Vitamin C reduced the expression of NF-κB however, no effect on the 
expression of P16 protein was noted (Fig.3.15).  
Altogether, we have shown that Vitamin C enhances the demethylation activity of the 
epigenetic drug 5-AZA and induces cell cytotoxicity. Inhibition of Snail expression 
leads to upregulation of p21 and simultaneous activation of GADD45 which are 
considered as the major effectors in inducing cell cycle arrest [Cayrol et al., 1998; 
Kearsey et al., 1995; Takahashi et al., 2004; Zhao et al., 2000], as shown in the HCC 
cell lines treated with 5-AZA and Vitamin C (Fig. 3.16). 
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Figure 3.15. Protein level expressions of Nf-κB and P15/P16 in Huh7 and HLE after 
treatment with 5-AZA and Vitamin C for 48 hrs. 
Western Blot data show the reduction of NfKB in both cell lines after treatment and a concomitant 
enhancement of P15/ P16 in Huh7 cells. 
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Figure 3.16. Proposed model of epigenetic changes induced by 5-AZA and Vitamin 
C leading to cell cycle arrest and inhibition of EMT in HCC. 
Vitamin C enhances active demethylation induced by 5-AZA, in converting 5-methyl 
cytosine to 5-hydroxymethyl cytosine by increasing the expression of TET2 and TET3. 
Induced demethylation leads to decrease in Snail expression and upregulation of 
GADD45.  Reduced Snail expression leads to upregulation of P21. The network of 
interactions between GADD45, P21, Cyclin B1 and PCNA lead to the arrest of cells in G1, 
S or G2/M phases of the cell cycle. On the other hand, increased expression of E-
cadherin by reduction of Snail leads to the inhibition of EMT. 
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3.11 Apoptosis and Stress array for HCCs  
 The pathscan apoptosis array based upon sandwich immunoassay principle provides 
simultaneous detection of 19 signaling molecules which are involved in the regulation of the 
stress response and apoptosis pathway. 
The analysis of pathscan array showed that the epigenetic modifiers 5-AZA and Vitamin C 
have an effect on the regulation of apoptosis and stress response pathway. 5-AZA and 
Vitamin C enhance the cleavage of caspase-3, caspase-7 and PARP in HLE cells but not in 
Huh7 cells. 5-AZA and Vitamin C increase the p38 MAPK and p53 but decrease TAK1 and 
ikBa ser 32/36 in both cell lines. Reduction of SAPK/JNK was observerd in HLE cells through 
combined treatment (Fig.3.17).  
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Figure 3.17. Pathscan apoptosis and cell stress array in HLE and Huh7 cells.  
5-AZA and Vitamin C have a different regulatory effect on the expression of apoptosis and cell stress 
response proteins. The data were compared to an untreated cell which is considered as 1. 
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3.12 Human Epigenetic Chromatin Modification Enzyme array for HCCs 
The PCR array provides the profile of the expression of 84 key genes (mentioned in 
the material and method section) encoding enzymes known or predicted to modify 
genomic DNA and histones to regulate chromatin accessibility and therefore gene 
expression (http://www.sabiosciences.com/rt_pcr_product/HTML/PAHS-085A.html). 
The de-novo and maintenance DNA methyltransferases, and the enzymes 
responsible for demethylation of CpG dinucleotides are represented by the array. 
Enzymes catalyzing histone acetylation, methylation, phosphorylation, and 
ubiquitination are also included on the array as well as the enzymes deacetylases 
and demethylases. Analyzing real-time PCR, results indicated that each of HCC cell 
lines consists of individual chromatin modified genes compared with primary 
hepatocytes (Fig 3.18). The largest differences of the chromatin status were 
observed in Huh7 cells and fewer differences were seen in HepG2 compared to 
PHH. Among four tested HCC cell lines 10 genes were upregulated which contained 
DNMTs (DNMT1, DNMT 3A) (Fig 3.19). 
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Figure 3.18. Chromatin modification enzyme profile array. 
A) Relative Fold regulation of Histone methyltransferases, SET Domain, Histone 
phosphorylation, Histone ubiquitination, Histone demethylases and DNA 
methyltransferases gene expression compared with PHH. B) Summary of alteration of 
chromatin modifier regulator gene expression in HCC compared to PHH (  : 
downregulated,     : upregulated) 
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Figure 3.19. Chromatin modification array in HCCs compared to PHH. 
Proportional Venn diagram depicting the overlap between upregulated chromatin 
modification enzymes identified among Huh7, HLE, AKN and HepG2 compared with 
human primary hepatocytes. The Venn diagram showed that ten common genes were 
upregulated in all 4 cell lines compared to Primary hepatocytes including DNMT1 and 
DNMT 3B. 
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3.13 Enzymatic activity of CYP450 
3.13.1 Gene Expression 
The expression of CYP450 was investigated in HCC cell lines after 48 hrs of 
treatment with 5-AZA and/or Vitamin C in 3 different passages (3 – 5 – 9). Results of 
mRNA expression indicated that the mRNA expression profile of CYP450 enzymes 
was altered depending on the confluency and the passage number of cell lines. 
Therefore, the passage number which showed the highest improvement of CYP 
enzyme gene expression was investigated in further experiments (Fig 3.20 - 3.21). 
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Figure 3.20. Phase 1 and Phase 2 metabolic mRNA Expression in HepG2 
cell line.  
5-AZA and Vitamin C change the expression of CYP450 genes expression after 
48 hrs of treatment. CYP3A4 gene expression increased 20% more in 5-AZA 
treated cells than unstimulated cells. Vitamin C and 5-AZA increase the UGT 
mRNA level 40% more than untreated HLE cells. The dash line is the indicator 
of human primary hepatocytes (GAPDH used as reference gene). 
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Figure 3.21. Phase 1 and Phase 2 metabolic mRNA Expression in Huh7 cell line.  
5-AZA and Vitamin C change the expression of CYP450 genes expression after 48 hrs of 
treatment. CYP1A1 gene expression increased 50% more in 5-AZA + Vitamin C treated 
cells than unstimulated cells. Vitamin C enhances the expression of CYP3A4 and 
CYP3A7 in Huh7 cells. 5-AZA and Vitamin C increases the UGT mRNA level 40% more 
than untreated Huh7 cells. The dash line is the indicator of human primary hepatocytes 
(GAPDH used as reference gene). 
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Figure 3.22. Phase 1 and Phase 2 metabolic mRNA Expression in HLE cell line.  
5-AZA and Vitamin C change the expression of CYP450 genes expression after 48 hrs of 
treatment. CYP1A1 gene expression increased 50% more in the combined treatment than 
unstimulated cells. Vitamin C and 5-AZA increase the UGT mRNA level 40% more than 
untreated HLE cells. The dash line is the indicator of human primary hepatocytes. 
(GAPDH used as reference gene).  
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Figure 3.23. Phase 1 and Phase 2 metabolic mRNA Expression in AKN1 cell line. 
5-AZA and Vitamin C change the expression of CYP450 genes expression. After 48 hrs of 
treatment CYP1A1 gene expression increased 30% more in the combined treatment than 
unstimulated cells. Vitamin C enhances the expression of UGT 40 % more than untreated 
cells. The dash line is the indicator of human primary hepatocytes (GAPDH used as 
reference gene).  
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3.13.2 Phase I and Phase II of enzyme activity 
Phase I enzyme activity was measured by fluorescence-based assays after 48 hrs of 
treatment. The results showed that 20 µM of 5-AZA enhanced the CYP1A1 activity in 
all four HCC cell lines. CYP3A4 enzyme activity seems to be induced by 5-AZA 
while, Vitamin C enhanced the effect of 5-AZA on CYP3A4 enzyme activity in AKN 1 
and HLE. 5-AZA increased the CYP2E1 enzyme activity in all four cell lines, 
interestingly in HePG2, Huh7 and AKN cells treated with 5-AZA, the enzyme activity 
of CYP2E1 overtakes Primary Hepatocyte enzyme activity and Vitamin C and 5-AZA 
can both enhance the level of CYP2C9. The UGT induced more in the combined 
treated cells than single treated. GST enzyme activity induced more by 5-AZA than 
combined treatment. However, the extension of the effect of Vitamin C and 5-AZA on 
CYP450 activity was different among the investigated HCC cell lines (Fig 3.24 - 
3.26). 
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Figure 3.24. Phase 1 and Phase 2 metabolic enzyme activity in the HepG2 cell line.  
5-AZA treatment increases the CYP1A1 and CYP3A4 enzyme activity approximately by 
10% and for CYP2C9 by 50% compared to untreated HepG2 cells after 48 hrs of 
treatment. UGT and GST also increased after 5-AZA treatment plus Vitamin C. The dash 
line shows the primary human hepatocyte enzyme activity as a gold standard. Data were 
repeated three times and the value in columns represents mean ± SD. P values were 
assessed by one way ANOVA, * p < 0.05 , ** p < 0.001, *** p < 0.001.  
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Figure 3.25. Phase 1 and Phase 2 metabolic enzyme activity in Huh7 cell line.  
5-AZA increases CYP1A1 (30%) and CYP3A4 (20%) CYP2E1 (10%) and CYP2C9 (30%) 
more than untreated Huh7 cells after 48 hrs of treatment. GST increased after treatment with 
5-AZA and Vitamin C. The dash line shows primary human hepatocyte enzyme activity as a 
gold standard. Data were repeated three times and the value in columns represents mean ± 
SD. P values were assessed by one way ANOVA, * p < 0.05 , ** p < 0.001, *** p < 0.001.  
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Figure 3.26. Phase 1 and Phase 2 metabolic enzyme activitiy in HLE cell line.  
5-AZA increases CYP1A1 and CYP2E1 enzyme activity and CYP2C9 50% more than 
untreated Huh7 cells after 48 hrs of treatment. UGT increased after treatment with 5-AZA 
and Vitamin C. The dash line shows primary human hepatocyte enzyme activity as a gold 
standard. Data were repeated three times and the value in columns represents mean ± 
SD. P values were assessed by one way ANOVA, * p < 0.05 , ** p < 0.001, *** p < 0.001.  
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Figure 3.27. Phase 1 and Phase 2 metabolic enzyme activity in AKN1 cell lines. 
The CYP1A1, CYP3A4 and CYP2E1 enzyme activity increased after treatment with 5-AZA 
for 48 hrs. CYP2C9 enzyme activity level improved more than 30% of the untreated cells. 
dash line shows primary human hepatocyte enzyme activity as a gold standard Data were 
repeated three times and the value in columns represents mean ± SD. P values were 
assessed by one way ANOVA, * p < 0.05 , ** p < 0.001, *** p < 0.001.  
 
 
N=3, n=3 
 Results
   
 
128 
 
3.14 Ammonia detoxification 
Detoxification of ammonia usually takes place in liver, but HCC cells lines lose the 
ammonia detoxification capacity. Therefore, we had interest to investigate the effect 
of epigenetic modifiers on ammonia detoxification pathway. HCC Cell lines were 
treated with 5-AZA and Vitamin C and the urea production was measured by 
florescence based assay. Our results show that 5-AZA enhanced urea production in 
all four cell lines which is induced by ornithine. In Huh7 the urea production reached 
the level of urea production of PHH after treatment of cells with 5-AZA for 48 hrs 
(Fig.3.28 and Fig. 3.29). 
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Figure 3.28. Detoxification of ammonia in HepG2 and Huh7 cell lines after 48 hrs of 
treatment with 5-AZA plus Vitamin C. 
The absorbance was measured by plate reader. 5-AZA and Vitamin C have an effect on 
urea production which it increased by adding NH4Cl and Ornithine (N=5, n=3). Red line 
shows primary human hepatocyte enzyme activity as a gold standard Data were repeated 
three times and the value in columns represents mean ± SD. P values were assessed by 
one way ANOVA, * p < 0.05 , ** p < 0.001, *** p < 0.001.  
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Figure 3.29. Detoxification of ammonia in HLE and AKN1 cell lines after 48 hrs of 
treatment with 5-AZA and Vitamin C.  
The absorbance was measured by plate reader.5-AZA and Vitamin C have an effect on urea 
production which it increased by adding NH4Cl and Ornithine (N=5, n=3). Red line shows 
primary human hepatocyte enzyme activity as a gold standard. Data were repeated three times 
and the value in columns represents mean ± SD. P values were assessed by one way ANOVA, 
* p < 0.05 , ** p < 0.001, *** p < 0.001.  
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4 Discussion 
4.1  Epigenetic modification in HCC 
4.1.1 Reduction of 5hmC in HCC  
Fine tuning the balance of DNA methylation vs. demethylation in relation to 
epigenetic modification has become a main focus  of cancer research in recent years 
[Esteller, 2008]. The loss of 5hmC as an indicator of demethylation has been 
suggested as prognostic marker in different types of cancer, and even to play a 
crucial role in the pathogenesis of cancers [Huang & Rao, 2014; Wang et al., 2014]. 
It was reported that 5hmC, in addition to its role as a DNA demethylase has a role in 
the regulation of genes involved in development, pluripotency, and the regulation of 
RNA splicing processes [Tan & Shi, 2012; Yan et al., 2014]. It was shown that 5hmC 
is a major epigenetic modification mark in an adult human liver, playing an important 
role in changes in hepatic gene expression in hepatocytes [Ivanov et al., 2013; 
Seeliger et al., 2013].  
In this thesis, we demonstrated that the generation of 5hmC is significantly reduced 
in hepatocellular carcinoma tissues and cell lines compared with healthy liver tissue 
and human hepatocytes. In line with other papers, our data clearly support the link 
between 5hmC ablation and tumor development [Baylin & Jones, 2011; Khan & La 
Thangue, 2011]. Furthermore, our results indicate that 5mC levels are enhanced in 
HCC tissues as well as in HCC cell lines. Altogether, our study provided a large scale 
screening of HCC tissues for detection of 5hmC and underlines that 5hmC could be a 
crucial diagnostic marker for HCCs which could be explored further for new HCC 
therapy strategies. 
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4.1.2 Downregulation of TET2 and TET3 leads to loss of 5hmC in HCCs 
TET proteins (TET1, TET2 and TET3) mediate the oxidation of 5mC to 5hmC. TET 
proteins were identified as dioxygenases that utilize two substantial factors: Fe(II) 
and 2-Oxyglutarate (2-OG), in order to oxidize the methyl group (CH3) of 5mC to form 
5hmC, thereby mediating active DNA demethylation [Griffiths & Gore, 2008; He et al., 
2011; Ito et al., 2010; Tahiliani et al., 2009]. The expression of these three TETs 
varies not only in different organs but also in the development of organs [Baylin, 
1997; Ito et al., 2010]. In various tumor types, a different TET family member has 
been reported to function as tumor suppressor [Bestor et al., 1988; Costello & Plass, 
2001; Das & Singal, 2004; Wu & Zhang, 2011]. Hence, identification of the most 
effective TET protein leading to cancer in the corresponding tissue is crucial to be 
investigated in different tumors. Recent evidence suggests that there is a remarkable 
correlation between decreased 5hmC levels and TET expression, resulting in 
progression of tumor and metastasis. This suggests that TET proteins might serve as 
a tumor suppressor in certain types of cancers [Haffner et al., 2011; Xu et al., 2011]. 
Recently, it was reported that the gene encoding TET2 but not TET1 and TET3 is 
frequently mutated in various tumors and was identified as the relevant tumor 
suppressor gene, which is mutated in leukemia [Delhommeau et al., 2009]. However, 
in breast cancer and prostate cancer, low expression of TET1 correlated with 
advanced cancer staging [Hsu et al., 2012] however, in other tumors such as 
colorectal cancer (CRC), the reduction of all three TET proteins has been reported 
[Guo et al., 2011a; Necula et al., 2015]. In addition, it was shown that the enzymes 
IDH1 or IDH2 are mutated in several cancers and play a crucial role in the reduction 
of 5hmC in cancer tissue [Lian et al., 2012; Liu et al., 2014b; Ye et al., 2013]. In 
HCCs the published results are contradicting each other regarding the role of TETs. 
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Liu et al. reported that a reduction of 5hmC is associated with the down-regulation of 
the TET1 protein in HCC [Liu et al., 2013] while Gao et al. claimed a down-regulation 
of TET1 and TET2 but no change in TET3 gene expression with a concomitant 
decrease of 5hmC in HCC [Gao et al., 2014]. Moreover, in another study by Yang et 
al., the decrease of all three TET genes was reported however in only three pairs of 
frozen human hepatocellular carcinoma tissue compared to matched normal liver 
tissue [Yang et al., 2013]. However, these three studies dealing with limited amounts 
of study samples.  
In our study we clearly found that only TET2 and TET3 but not TET1 genes are 
significantly reduced in HCC tissue and in hepatocellular carcinoma cell lines. These 
changes were paralleled by a concomitant decrease of both IDH genes and 5hmC as 
well as a significant increase of 5mC. The expression of TET1 in our healthy liver 
samples was in almost all samples undetectable. Recently, it was shown that TET1 
plays a crucial role in the early development of self-renewal pattern in embryonic 
stem cells and has been implicated in epigenetic regulation of stem cells and 
genomic imprinting [Baylin, 1997; Huang et al., 2013; Ito et al., 2010; Yamaguchi et 
al., 2013]. These findings suggest a more crucial role for TET1 in embryogenesis. In 
the study by Neri et al. it was shown that TET1 is regulated by the stemness factors 
such as; Oct 3/4, Nanog and c-Myc. Therefore, it is implicated in pluripotency of 
transcriptional network of ESC. They showed that TET1 is switched off in adult cells 
and tissues. The TET1 downregulated through H3K27me3 histone mark deposition 
which leads to genome-wide reduction of 5hmC [Neri et al., 2015]. Therefore, this 
thesis focused on the effect of TET2 and TET3 on HCC development.  
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The changes in 5hmC and 5mC  in tumor tissues are confirmed by other studies [Liu 
et al., 2013; Yang et al., 2013], including our results. There are conflicting reports 
regarding to decisive TET in HCCs. But what might be the reasons for these 
conflicting results? An additional explanation could be simply the use of specific 
analytical tools. It has been reported that the expression of typical housekeeping 
genes include glyceraldehyde-3-phosphate dehydrogenase (GAPDH), beta-actin 
(ACTB), could also be affected in the course of HCC development and a significant 
difference in these housekeeping genes was reported in HCC tissues compared to 
normal liver [Waxman & Wurmbach, 2007]. The use of inappropriate genes for 
normalization can lead to an over- or under-estimation of the fold-changes or to 
misinterpretation of the results. Therefore, using inconstant genes like ACTB for the 
normalization of the q-PCR may lead to different interpretation of the TET gene 
expression in HCCs tissue samples. We have observed the different expression of 
GAPDH and ACTB in HCC tissue samples which is known to be deregulated in 
HCCs caused by viral infections such as HBV and HCV [Waxman & Wurmbach, 
2007]. We used ß2M among 4 tested housekeeping genes including; GAPDH, 
ACTB, HPRT, ß2M as a reference gene because the expression of ß2M was the only 
which was constant among all tissue samples. 
It is well established that 5-AZA causes the reduction of the DNA methylation status 
by inhibiting DNMT through passive demethylation pathway [Christman, 2002]. 
Recently, the active demethylation of DNA through oxidation of 5mC to 5hmC 
mediated by TET proteins was discovered [Tahiliani et al., 2009]. To our knowledge, 
our study was the first to demonstrate that 5-AZA reduces the methylation status of 
DNA not only by triggering the passive demethylation pathway of DNA [Christman, 
2002] - but also the active demethylation pathway conversion of 5mC to 5hmC by 
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inducing TET2 and TET3 proteins. Our finding was further substantiated when 5-AZA 
was unable to induce 5hmC inTET2 knocked-down HCC cell lines suggesting the 
effect of 5-AZA on TET-2 and also suggesting a crucial role for TET2 in 5hmC 
induction and in the pathogenesis of HCC. This was further underlined by our 
findings that 5-AZA inhibited HCC tumor cell growth; a decline of 5mC and a strong 
increase of 5hmC. However, a detailed mechanism of how 5-AZA affects the activity 
of TET proteins remains to be further elucidated [Sajadian et al., 2015]. 
4.1.2.1 Vitamin C facilitates the effect of 5-AZA on oxidation of 5mC to 5hmC 
In this study we have shown that Vitamin C enhances the demethylation efficacy of 
5-AZA by increasing the expression of TET2 and TET3 in HCC. Our result showed 
that Vitamin C is able to enhance the epigenetic activity of 5-AZA, thus compensating 
for a higher dose of 5-AZA (20 M) in which it can facilitate active-demethylation.. As 
it was mentioned before, the catalytic activity of TET dioxygenases for oxidation of 
5mC depends on two crucial factors, Fe(II) and 2-oxoglutarate and they are only 
active when iron is present in Fe(II) status [Pastor et al., 2013]. In the absence of 
substrate, iron left in a high level of oxidation state, which inhibits further catalysis 
[Monfort & Wutz, 2013]. Vitamin C as an electron donor for reducing iron atom is able 
to rescue the dioxygenase enzyme and restore the catalytic activity for the next 
cycle. Several histone and DNA modifying enzymes belong to Fe(II) and 2-
oxoglutarate dependent family including, JumonjiC-domain- containing histone 
demethylases (JHDMs) which can facilitate multiple function in adjustment or change 
of chromatin remodeling and TET DNA hydrolyses that catalyze the oxidation of 
methyl groups from 5mC [Monfort & Wutz, 2013]. In a study by Venturelli et al., it was 
shown that a pharmacological doses of Vitamin C (8 mM) inhibited the DNMT but not 
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HDAC activity in a melanoma cell line and up-regulated 32 miRNA mainly involved in 
tumor suppression and drug resistance pattern [Venturelli et al., 2014]. These studies 
suggest a crucial role of Vitamin C in chromatin remodeling which may prove 
beneficial in future cancer therapy. 
4.1.3 Effect of the 5-AZA and Vitamin C on cell death pathway and stress 
signaling  
We investigated the level of the expression of caspase 3, caspase 9 and PARP 
proteins to see the effect of treatment on apoptosis cascade. We didn’t detect 
cleavage of caspase 3 and PARP protein in HCCs after 48 hrs of treatment with 5-
AZA and Vitamin C. Balance of survival and death signals under normal and 
pathological conditions determines cell fate. Therefore, we used Pathscan stress and 
apoptosis signaling antibody array kits which included 19 signaling molecules that 
are involved in the regulation of the stress response and apoptosis mechanisms 
(Pathscan Array, Cell Signaling, MA; USA) to investigate signaling pathways 
molecules which are affected by 5-AZA and Vitamin C treatment and drives cell cycle 
arrest. 
A slight increase of the cleavage of caspase 3 and 7 as well as BAD was observed 
after treating HLE cells with 5-AZA and Vitamin C but not in Huh7 cells. Survivin acts 
as anti-apoptotic molecule and inhibits caspase 3 activity [Shin et al., 2001]. 
Pathscan array analysis showed that 5-AZA elevated the expression of the survivin 
protein in both cell lines, however when 5-AZA was combined with Vitamin C, the 
level of survivin was reduced which renders HCC cells more susceptible to death 
pathways [Sugawara et al., 1999]. On the other hand the combined treatment causes 
the increase in BAD protein expression (BCL2 Associated Death receptor) which is a 
caspase independent pro-apoptotic member of BCL-2 gene protein. Our results 
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suggest that the increase of the BAD protein by 5-AZA and Vitamin C treatment 
might be caused by attenuation of NF-κB and AKT proteins. AKT inhibits apoptosis 
by activating anti-apoptosis proteins such as NF-κB and through inactivation of pro-
apoptotic proteins such as BAD [Kamada et al., 2007; Ozes et al., 1999]. 
TAK1 is a member of MAPKKK family and has an activatory effect on [Ninomiya-Tsuji 
et al., 1999]. Combined treatment of 5-AZA and Vitamin C results in a reduction of 
TAK1 (TGFβ-activated kinase 1) which is in association with the reduction of NF-κB 
in HCC cells after treatment. In addition, it was shown that Snail activation is 
correlated to NF-κB activation and NF-κB signaling pathway and inhibits the 
expression of Snail transcription[Julien et al., 2007]. Apparently our data suggests 
that Vitamin C together with 5-AZA are implicated in the influencing snail expression 
through NF-kB signaling [Zhang et al., 2010]. Apparently our data suggests that 
Vitamin C together with 5-AZA are implicated in the NF-κB signaling pathway and 
inhibits the expression of Snail transcription Interestingly, our results indicate that the 
combination of 5-AZA and Vitamin C is able to enhance p38MAPK but inhibits 
SAPK/JNK which leads to increase of p53 [Jing & Anning, 2005]. In addition, 
P38MAPK has an inhibitory effect on ERK expression resulting in the inhibition of cell 
survival. Recently it was shown that high level of MAPK signaling (ERK) leads to an 
increased miR-29b expression. miR-29b attenuates TET1 expression which drives 
decreased of 5hmC level resulting in enhancement of DNA methylation. This finding 
suggests that drug treatment that target TET may synergize with MAPK suppression 
[Taylor et al., 2016]. 
Furthermore, our results show that a combination of 5-AZA and Vitamin C is able to 
activate ATM/CHK1/CHK2/P53 signaling pathways in HLE cells which lead to S/G2 
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cell cycle arrest and increase of caspase 3 and caspase 7 but not Huh7 cells. 
However, in Huh7 cells  the combined treatment of 5-AZA and Vitamin C leads to an 
increased expression of p16 and p21 which might lead to the inhibition of cyclin D/E 
[Harper et al., 1995] and reduction of PCNA expression resulting in G0/G1 arrest 
[Flores-Rozas et al., 1994]. Figure 4.1 summarizes the death and stress response 
factors which are triggered by 5-AZA and Vitamin C through epigenetic changes 
which are based on the findings of this study and literature.  
 
 
Figure 4.1. Effect of 5-AZA and Vitamin C on Cell cycle pattern of cells.  
5-AZA and Vitamin C are able to trigger different crucial cell cycle checkpoints, tumor 
suppressors and genes which sensitize the cells to death (based on this study findings, 
pathways regulation is based on literatures) 
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4.2  Consequences of active demethylation in HCCs  
As a consequence of induction of DNA demethylation by using 5-AZA and Vitamin C 
in our HCC cell lines, an inhibition of some oncogenes like Snail and reactivation of 
some tumor suppressors like GADD45 and p21 was observed. The enhanced 
expression of GADD45 combined with the changes in expression of PCNA and 
Cyclin B1 induced cell cycle arrest in HCC in the G1 and G2 phase, respectively.  
Dynamic epigenetic changes mark EMT by the inducible expression of Snail [Javaid 
et al., 2013]. Snail governs cell cycle progression by repressing P21 [Takahashi et 
al., 2004]. While Snail expression is essential for tumorigenesis, reduction in Snail 
expression in cancer cells is considered essential in limiting tumor cell progression by 
inducing cell cycle arrest [Sugimachi et al., 2003; Wu & Zhou, 2010]. A recent study 
reports that 5-AZA inhibited the inducible Snail expression in cultured hepatocytes 
and also suggests the possible involvement of miR29b in Snail regulation [Cicchini et 
al., 2015]. Based on these studies and our recent report [Sajadian et al., 2015], we 
propose that the downregulation of Snail expression is mainly attributed to an 
increase in TET activity by a combination of 5-AZA and Vitamin C in an indirect 
manner involving negative or positive regulators. The upregulation of Snail 
repressors such as NF-κB or some miRs (e.g.: miR337), could play a significant role 
in limiting Snail expression [Cicchini et al., 2015]. In addition, it was shown that 
miR337 has an inhibitory effect on Snail and can increase HNF-4α, which is required 
for controlling many genes involved in liver development and metabolism [Lemaigre, 
2009; Schulz et al., 2013]. We observed the downregulation of NF-κB which might be 
related to the reduction of TAK1 in HCCs after treatment with 5-AZA and Vitamin C. 
However, the details of this mechanism need to be further investigated.  
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The growth arrest and DNA damage-inducible GADD45 genes are central players 
that are upregulated during cellular stress. Activation of GADD45 results in several 
processes of growth arrest, DNA repair, survival or apoptosis [Tamura et al., 2012]. 
Hypermethylation of the GADD45 promoter is found in various cancers including 
HCCs, which leads to downregulation of GADD45 expression and promotes tumor 
progression [Tamura et al., 2012; Zerbini & Libermann, 2005]. It was reported that 5-
AZA enhances the expression of GADD45 in colon cancer cells resulting in the 
induction of apoptosis [Schneider-Stock et al., 2005]. GADD45 proteins are also 
reported to induce cell cycle arrest by direct interaction with P21, PCNA and Cyclin 
B1 (through CDK1/Cyclin B1 complex) thereby inducing cell cycle arrest at the 
various phases of the cell cycle [Liebermann & Hoffman, 2003; Liebermann & 
Hoffman, 2007; Zhao et al., 2000]. P21 is also known to have a PCNA binding 
domain towards its carboxyl terminal and to inhibit the replication of DNA at the S 
phase [Flores-Rozas et al., 1994]. In the same line of evidence, it was also reported 
that binding of P21 to PCNA induces cell cycle arrest at the G1 or G2 level [Cayrol et 
al., 1998]. In agreement with the above reports, we have seen an enhanced 
expression of GADD45 in our HCC cells treated with a combination of 5-AZA and 
Vitamin C. It has been reported recently that GADD45 could also induce active 
demethylation processes via nucleotide excision repair or base excision repair 
pathway [Delatte & Fuks, 2013] which might also be associated with the induction of 
active demethylation via 5-AZA and Vitamin C, as shown in this study. The possible 
pathways that were affected by 5-AZA and Vitamin C though triggering GADD45 and 
Snail were summarized in Fig 4.4. 
The most common problem associated with tumor cells is their increased resistance 
to programmed cell death. Induction of E-cadherin expression is considered as an 
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important step in sensitizing tumor cells towards apoptosis [Qiu et al., 2010]. E-
cadherin modulates apoptosis by coupling with the death receptors DR4/DR5. 
Consequently, increased expression of E-cadherin sensitizes cancerous cells to cell 
death [Lu et al., 2014]. Therefore, reactivation of E-cadherin could be an important 
target for epigenetic therapy in HCC. 5-AZA, when used either alone or in 
combination with other drugs, was shown to enhance the expression of E-cadherin in 
HCC cell lines and lung epithelial cells, respectively [Qiu et al., 2010]. In 
differentiated hepatocytes, 5-AZA not only maintains the expression but also inhibits 
downregulation of E-cadherin [Cicchini et al., 2015]. In the present study, since Snail 
is a direct repressor of E-cadherin [Cano et al., 2000], reduction of Snail was 
expected to lead to an enhanced expression of E-cadherin. In line with this, we 
observed an increase in the expression of E-cadherin by a combination of 5-AZA 
plus Vitamin C. An increase in the number of cells undergoing cell death with the 
combined treatment is probably due to both the arrest of cells by reduced Snail and 
the increased sensitivity of the cells towards cell death by the enhanced expression 
of E-cadherin. 
An increase in E-cadherin expression upon independent treatment with Vitamin C 
further highlights the role of Vitamin C in epigenetic regulation. Use of Vitamin C 
could therefore support the maintenance of epithelial morphology of the cells and 
thus prevent the MET, which is involved in cancer cell invasion and progression 
[Chen et al., 2013b]. Figure 4.2 proposed signaling pathways which may affected by 
5-AZA and Vitamin C treatment in HCC cells with an alteration of GADD45 and Snail 
protein based on the findings of this study. 
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4.3 Induction of metabolic activity of HCC cell line by alteration of epigenetic 
landscape 
The hepatic function of hepatocytes, in particular, the xenobiotic biotransformation 
capacity is reduced during isolation and culture. This is mainly attributed to the loss 
of the differentiated hepatic phenotype during in-vitro culture [Snykers et al., 2009]. 
The stabilization of a differentiated hepatic phenotype frequently relies on the binding 
Figure 4.2. Effect of 5-AZA and Vitamin C on Snail and GADD45 and downstream 
regulators.  
The combination of 5-AZA and Vitamin C inhibits Snail protein expression in HCCs and 
induced GADD45 expression. Snail and GADD45 are both crucial transcriptional 
regulator which can change the fate of cells and make them more sensitize to death and 
inhibits the endless proliferation of HCCs (the effect of 5-AZA and Vitamin C on different 
pathways and the contribution of these pathways are based on findings of this study)  
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of DNA binding protein like: liver-enriched transcription factor (LETFs). Histones and 
other proteins assist chromatin fibers to condense the DNA, therefore, modification of 
chromatin status through DNA methylation and histone modification is substantial for 
the activation of transcriptional factors for stabilization of hepatic phenotype. It was 
shown that inhibition of HDAC and DNA methylation were contributed to down-
regulation of genes which are involved in cellular proliferation but an up-regulation of 
genes responsible for xenobiotic metabolism [Snykers et al., 2009]. Therefore, 
regulation of epigenetic modification may play a substantial role in gene transcription, 
with maintenance of differentiated characteristics (geno/phenotype) of primary 
hepatocytes. In our study we have shown that 5-AZA and Vitamin C inhibits the 
proliferation of HCC cell lines with an enhancement of active demethylation pathway 
associated with increase of TET proteins expression which may contributes to 
activation of some crucial transcription factor which are responsible for metabolic 
activity of hepatoma cell lines. 
4.3.1 CYP metabolic activity 
PHH in culture and hepatoma cell lines are the most common standards in in vitro 
systems to evaluate drug metabolism and toxicity. Unfortunately, cultured 
hepatocytes lose their drug metabolic capacity rapidly in culture and they have large 
batch-to-batch variations. In contrast, hepatoma cell lines have an unlimited life span 
and they consist of a more stable phenotype than primary hepatocytes, are 
constantly available, but they have a low CYP metabolic activity [Rodriguez-Antona 
et al., 2002]. Different factors are suggested to be responsible for a reduction of CYP 
activities including inactivation of CYP enzymes, instability of apoprotein or 
decreased of mRNA production [Rodriguez-Antona et al., 2002]. Indeed, It was 
shown that the expression of key inhibitory (LIP, HNF-3α) and activatory (HNF4α, 
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RCR-αLAP) transcription factors and liver enriched transcription factors (LETFs) are 
modified in hepatoma cell lines which is linked to the reduction of CYP expression 
and functionality of these cells [Rodriguez-Antona et al., 2002]. Furthermore, various 
transcription factors such as PXR, CAR and HNF4α can modulate the regulation of 
specific CYP450 genes like CYP3A4 and CYP2E1 [Snykers et al., 2009]. In the same 
line of evidence, it was shown that Snail has an inhibitory effect on HNF4α which is 
crucial for liver development and for controlling the expression of many genes 
contributed to drug metabolic pathway including such as CYP450 enzymes, UDP-
glucoronosyltransferase and sulfotransferases [Gonzalez, 2008].  
Multiple studies investigated the effect of epigenetic modifiers like DNMTi and HDACi 
on alteration of CYP activity in HCC cell lines [Snykers et al., 2009]. Therefore, in the 
present study we investigated the effects of 5-AZA and Vitamin C as epigenetic 
modifiers on CYP activities which can suppress the cell proliferation and 
differentiation with the most likely hepatocyte characteristics and higher level of drug 
metabolism enzymes. We have shown that 5-AZA and Vitamin C have an inhibitory 
effect on Snail transcription factor either by inhibiting TAK/NF-κB pathway molecules 
or inducing some miRs, which requires further investigation. Therefore we conclude 
that inhibition of Snail by 5-AZA and Vitamin C may lead to an increase of CYP450 
activities especially of CYP3A4. 
Screening for chromatin modification enzymes showed that each cell line has an 
individual chromatin status which may lead to discrete CYP catalytic activities of cells 
after treatment with the epigenetic modifiers; 5-AZA and Vitamin C. For instance, the 
chromatin enzyme array of HepG2, which is commonly used to investigate drug 
metabolism, is more similar to primary hepatocytes and in opposite, Huh7 illustrated 
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the most alteration of genes responsible for chromatin formation in compared with 
primary hepatocytes.  
Our results also showed that 5-AZA and Vitamin C have stronger effects on CYP450 
catalytic activities in the HepG2 cell line than in other investigated HCC cell lines. 
Previously, we have shown that for each CYP isoenzyme, all hepatoma cell lines 
have a cell certain passage in which maximum CYP activity was seen [169]. 
Interestingly, our results showed that the CYP expression is dependent on the 
confluency and passage number which is in line with our previous data [Lin et al., 
2012]. Regarding to the cell confluency, in another study it was also shown that when 
Huh7 cells are confluent, the CYP3A4 isoenzyme activity increased which is related 
to increase of PXR and HNF4 mRNA expression. When the confluency of cells is 
high, they avoid proliferating and resulting in formation of dense layer of cells with 
more hepatocyte cells characteristic including higher level of albumin, glucose-6-
phosphate, drug metabolizing enzymes and transcriptional factors [Sivertsson et al., 
2010]. They have shown that treatment of confluent Huh7 cells with rifampicin, a well-
known inducer of CYP3A4 through its interaction with PXR, increased the CYP3A4 
activity in 4-weeks confluent cells. This finding indicates the role of PXR receptor in 
CYP transcription activity. 
We observed the variant regulation of CYP isoforms mRNA level in HCC cells over 
the whole culture period. For example, HepG2 indicated better CYP transcription 
level at passage 8, while Huh7 cells showed highest CYP isoenzyme activity at 
passage 9, AKN cells also in passage 9 and in HLE cells the best CYP activity was 
observed at passage 5. Our results suggest that the maximum increase of CYP 
catalytic activity though epigenetic modification of hepatoma cells (5-AZA and 
Vitamin C) is after 48 hrs of treatment. However, the mechanism(s) behind of this 
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increase on CYP catalytic activity through epigenetic modification in HCCs needs 
further investigation. 
4.3.2 Ammonia detoxification 
Acute liver damage results in dys-synthesis of urea, which causes high blood 
ammonia concentrations and even hepatic coma [Patzer II et al., 2002]. The number 
of patients with liver function failure has steadily increased over the years [Tang et 
al., 2008], therefore it is crucial to discover a way to reduce ammonia toxicity for 
clinical therapy aspect. Bio-artificial Liver (BAL) therapy has been developed to 
bridge the need for liver transplantation and liver regeneration [Nussler et al., 2011; 
Patzer II et al., 2002]. However, lack of stable and conveniently usable human 
hepatocyte is the major problem of BAL therapy [Nussler et al., 2006]. Primary 
hepatocytes have the limitation of availability, losing their functionality after culture or 
cryopreservation damaging. Porcine hepatocytes were used as a source of 
hepatocytes in BAL therapy [Tang et al., 2008].  However, the major problems with 
use of animal hepatocytes are xenotransplantation-related risks and infection risks 
[Nussler et al., 2006; Nussler et al., 2011]. Hepatoma cell lines would be a possible 
good alternative for primary hepatocytes but their ammonia detoxification capacity is 
extremely low [Mavri‐Damelin et al., 2008; Nibourg et al., 2012; Tang et al., 2008]. 
Therefore developing a method which improves the ammonia detoxification of HCC 
cell lines would be highly desirable. We were able to induce the detoxification of 
ammonia significantly in all four HCC cell lines by inducing epigenetic modifications 
on chromatin by using Vitamin C and 5-AZA which was most significant in AKN1 
cells. 
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5 Conclusion and outlook 
The data presented in this study indicates the reduction of TET2 and TET3 
expression and activity with concomitant decrease of 5hmC in Hepatocellular 
Carcinoma tissues and cell lines. Therefore, epigenetic drugs that mediate 
conversion of 5mC to 5hmC through modulating TET activity may find a broad use in 
the treatment of HCC. This study identifies a novel function of 5-AZA in promoting 
TET-mediated generation of 5hmC suggesting that availability of 5-AZA in cancer 
cells will have different effects on various epigenetic marks. However, the mechanism 
of how 5-AZA mediates TET expression needs to be investigated. Apparently, the 
TET genes possesses the CpGs island in their promoter region which undergoes 
demethylation by 5-AZA and so bisulfite sequencing of the promoter of TET genes 
may address this question. 
We have shown that Vitamin C enhances DNA demethylation effect of the epigenetic 
drug 5-AZA by modulating TET activity. Our study has further added value to the 
growing evidences of Vitamin C as an epigenetic player. Increased TET expression 
leading to a concomitant increase in demethylation by a combination of an epigenetic 
drug with cofactors such as Vitamin C might prove to be a beneficial and attractive 
strategy for cancer therapy in the future. In vivo studies may provide an overview of 
how HCC tissue can be treated by the combination of 5-AZA and Vitamin C in tumor 
micro-environment. 
Epigenetics plays a crucial role in tumorigenesis by modulating EMT and cell cycle 
proliferation pathways. Inhibition of Snail transcription factor with simultaneous 
activation of GADD45 are considered as major effectors in inducing cell cycle arrest, 
as shown in the HCC cell lines when treated with 5-AZA and Vitamin C. Our data 
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suggest that 5-AZA in combination with Vitamin C is implicated in the NF-κB signaling 
pathway, thereby inhibiting the expression of Snail transcription. Reduction in Snail 
expression in HCC cells is considered as an essential limiting factor in tumor cell 
progression by inducing cell cycle arrest through activation of p21. Further study on 
miRs, which affect the Snail (miR 337) expression through treatment, should be 
investigated to elucidate the complete mechanism which is triggered by the 
epigenetic changes. In order to address further, the potential effect of 5-AZA and 
Vitamin C on crucial transcription factors such as Snail and GADD45, an evaluation 
of the siRNA knockdown study is important. 
Furthermore, we observed an increase in the expression of E-cadherin by a 
combination of 5-AZA plus Vitamin C. An increase in the number of cells undergoing 
cell death with the combined treatment is probably due to both the arrest of cells by 
reduced Snail and the increased sensitivity of the cells towards cell death by 
enhanced expression of E-cadherin. An increase in E-cadherin expression upon 
independent treatment with Vitamin C further highlights the role of Vitamin C in 
epigenetic regulation. Use of Vitamin C could therefore support the maintenance of 
epithelial morphology of the cells and thus prevent MET. To confirm the anticancer 
effect of the epigenetic treatment on HCCs, EMT-MET transition should be analyzed 
more in detail. It would be also interesting to look at the differentiation and drug 
resistance characteristic of the cells which might be correlated to EM-MET transition.  
Moreover, it was shown that inhibition of HDAC and DNA methylation down-regulates 
genes involved in cellular proliferation and up-regulates the genes responsible for 
xenobiotic metabolism. In this study, we have shown that 5-AZA and Vitamin C 
inhibits the proliferation of HCC cells through TET-mediated active demethylation, 
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which may contributes to activation of some of the crucial transcription factors which 
are responsible for metabolic activity of hepatoma cells. Our results also showed that 
5-AZA and Vitamin C have stronger effects on CYP450 catalytic activity in the 
HepG2 cell line compared to other investigated HCC cell lines. 
Though we were able to induce the detoxification of ammonia significantly in all four 
HCC cell lines by changing the epigenetic pattern of chromatin using Vitamin C and 
5-AZA, the results were found to be more significant in AKN1 cells. However, 
detailed analysis of genes and transcription factors which are responsible for 
CYP450 activity needs to be done in order to understand the mechanism/s which 
is/are implicated by epigenetic modifications. Therefore, the siRNA knock down study 
of transcriptional regulators of CYP450 genes such as HNF4α should be completed. 
Furthermore, it would be also interesting to investigate if the CYP450 activity is 
getting improved by using the combination of methylation inhibitors (e.g.: 5-AZA, 
Vitamin C) and Histone deacetylases inhibitors (e.g.: TSA) in HCC cell lines. 
Our result showed the combination of 5-AZA and Vitamin C increased the ammonia 
detoxification. The effect of epigenetic modification on urea pathway needs to be 
investigated more in detail, especially screening of genes and transcription factor 
which are implicated in urea pathway. In addition, in vivo confirmation using Animal 
model would be a promising way to address the potential effect of epigenetic 
modification on ammonia detoxification. 
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6 Abbreviations 
7-AAD 7-amino-actinomycin D 
AID Cytidine Deaminase 
AML Acute myeloid leukemia 
ANOVA  Analysis of Variance 
AP Alkaline phosphatase 
APOBEC 
Apolipo protein B mRNA editing enzyme catalytic 
peptide 
5-AZA 5-Azacytidine 
5-AZA-dC 5- Azacytidine-2’-deoxycitidine 
BER Base Excision Repair 
BFC  7-Benzyloxy-4(trifluormethyl)coumarin  
bp  Base pare  
BSA  Bovine serum albumin  
C Cytosine 
5caC 5 carboxylcytosine 
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CDK-2 Cell division kinase 2 
CDNA Complementary DNA 
Cou  Coumarin  
CRC Colorectal cancer 
DBF  Dibenzylfluoresceine  
DMEM  Dulbecco’s Modified Eagle’s Medium  
DMSO  Dimethyl sulfoxide  
DNA  Deoxyribonucleic acid  
dNTP  Desoxynukleotidtriphosphat  
DNMT DNA Methyl Transferase 
DPBS  Dulbeccos's Phosphate Buffered Saline  
EMT Epithelial Mesenchymal Transition 
ER Estrogen receptor 
FACS Fluorescent Activated Cell Sorting 
FBS Fetal Bovine Serum 
FC Flow cytometry 
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5fC 5 formylcytosine 
FITC Fluorescein Isothiocyanate 
FACS Fluorescent Activated Cell Sorting 
FBS Fetal Bovine Serum 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase  
GFs Growth Factor(s) 
GSH  Glutathione conjugate  
H3K9 Histone H3 lysine 9 
HAT Histone Acetylation Transferase 
HBV Hepatitis B 
HCC Hepatocellular carcinoma 
IDAX 
inhibitor of the Dvl and axin complex; also known as 
CXXC4 
IDH  Isocitrate dehydrogenase 
IF Immunofluorescrnce 
IHC Immunohistochemistry 
IDH  Isocitrate dehydrogenase 
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IF Immunofluorescrnce 
Kda Kilodalton 
LDH Lactose dehydrogenase 
MAPK Mitogen activated protein kinase 
5mC 5 methylcytosine 
MET Mesenchymal-epithelial transition 
MSC Mesenchymal Stem Cells 
4-MU 4-Methylumbelliferone 
NAFLD non-alcoholic fatty liver disease 
NH4OH Ammonium Hydroxide 
nM Nanomolar 
2OG 2-oxoglutarate 
O2 Oxygen 
PAGE Polyacrylamide Gel Electrophoresis 
PBS Phosphate-Buffered Saline 
PCNA Proliferating cell nuclear antigen 
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PCR Polymerase Chain Reaction 
PE Phycoerythrin 
Pen/Strep Penicillin/Streptomycin 
PI Propidium Iodide 
PHH Primary Hepatocytes 
pM Picomolar 
PMSF  Phenyl-Methyl-Sulphonyl-Fluoride 
PR Progesterone receptor 
qRT-PCR quantitative Real Time Polymerase Chain Reaction 
RNA Ribonucleic Acid 
Rpm Revolution Per Minute 
RT Room Temperature 
SCF Stem Cell Factor 
SDF Stromal Derived Factor 
SDS Sodium Dodecyl Sulphate 
Si-RNA Short interference RNA 
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SOCS1 Suppressor of Cytokine Signaling 1 
SPCS1 Signal Peptidase Complex Subunit 1 
TCA Trichloro Acetic Acid 
TEMED N, N, N’, N’-tetramethylene diamine 
TET Ten- eleven-translocation 
TGF-β Transforming Growth Factor Beta 
Tm Melting Temperature 
TNF Tumour Necrosis Factor 
Tris Tris-hydroxymethylaminomethane 
TIMP Tissue inhibitor of metallo protinases  
TDG Thymidine DNA Glycosylase 
TSA Trichostatin A 
UHRF1 
Ubiquitin-like protein with PHD and RING finger 
domain 1 
µg Microgram 
µl Microliter 
µM Micromolar 
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